UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Form 10-K

þ	ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2004

o	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ________to _________

Commission File Number 0-21185

aaiPharma Inc.

2320 Scientific Park Drive, Wilmington, NC 28405
(Address of principal executive offices) (Zip code)

(910) 254 7000
(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

None

Securities registered pursuant to Section 12(g) of the Act:

COMMON STOCK, $0.001 PAR VALUE PER SHARE
(Title of class)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. o

Indicate by check mark whether the registrant is an accelerated filer (as defined in Exchange Act Rule 12b-2)

The aggregate market value of the registrant’s common stock held by non-affiliates of the registrant as of June 30, 2004, computed by reference to the closing price of the common stock on that date was $ 59,666,943.

The number of shares outstanding of registrant’s common stock as of April 1, 2005 was 28,585,582 shares.

TABLE OF CONTENTS

PART I

Item 1. Business

The terms “we”, “us”, “our” or “aaiPharma” in this Form 10-K include aaiPharma Inc., its corporate predecessors and its subsidiaries, except where the context may indicate otherwise. Our corporation was incorporated in 1986, although its corporate predecessor was founded in 1979.

Our principal executive offices are located at 2320 Scientific Park Drive, Wilmington, North Carolina (telephone: 910-254-7000).

Our Internet address is www.aaipharma.com. We make available through our internet website our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section 13(a) of the Securities Exchange Act of 1934 as soon as reasonably practicable after we electronically file such material with, or furnish it to, the Securities and Exchange Commission.

Trademarks and Trade Names

We own the following registered and unregistered trademarks: Darvocet®, Darvon®, Darvon-N®, Darvocet-N®, Darvocet A500™, Brethine®, ProSorb®, ProSorb-D™, Lynxorb™, ProSLO®, ProSLO II™, ProCore®, Oramorph® SR, ProLonic AQ™, Roxanol™, Roxicodone®, AzaSan®, aaiPharma®, AAI®, AAI Development Services™ and Applied Analytical Industries®. AzaSan® is a registered trademark owned by us and licensed to Salix Pharmaceuticals. Unless the context otherwise requires, references in this document to Darvon are to Darvon® and Darvon-N® collectively and references to Darvocet are to Darvocet-N® and Darvocet A500™. We also reference trademarks owned by other companies. Prilosec® is a registered trademark of AstraZeneca AB, Dolophine® is a registered trademark of Eli Lilly and Company, Allegra-D® is a registered trademark of Aventis Pharmaceuticals Inc., Proventil® is a registered trademark of Schering Corporation, Volmax® is a registered trademark of GlaxoSmithKline, Imuran® is a registered trademark of Prometheus Laboratories Inc., M.V.I.® and Aquasol® are registered trademarks owned by Mayne Pharma (USA) Inc., Duraclon® is a registered trademark owned by Fujisawa Healthcare, Inc. and licensed to us, Avinza® is a registered trademark owned by Ligand Pharmaceuticals, Inc., MS Contin® is a registered trademark owned by Purdue Pharma, L.P., and Kadian® is a registered trademark owned by Alpharma Inc. All references in this document to any of these terms lacking the “®” or “TM” symbols are defined terms that reference the products, technologies or businesses bearing the trademarks with these symbols.

Overview

Our company was founded in 1979 to provide laboratory services, such as analytical testing on pharmaceutical compounds, to pharmaceutical companies. In the 1980s, we increased our service offerings to include clinical trials material manufacturing, microbiological testing and regulatory and quality consulting. We continued expanding our scientific base in the 1990s by adding bioanalytical, biotechnical, commercial manufacturing and human clinical trials management capabilities. We offer our clients scientific solutions to their pharmaceutical

development needs. In our history, we have worked with large and small companies offering a wide range of services across the drug development continuum.

We also use our drug development capacity to work on our own internal product pipeline. In the 1990s, we helped establish two companies which received approvals for products we developed. We also entered into various shared-risk arrangements with companies to bring pharmaceutical products to the market based on development work we conducted.

In 2001, we began pursuing a product acquisition strategy to expand our operations as a specialty pharmaceutical company. Between August 2001 and April 2002, we acquired three lines of pharmaceutical products. In late 2003, we completed the acquisition of a line of pain products from Elan Corporation, plc (“Elan”). In April 2004, we sold the multivitamin infusion product line that we had acquired in 2001.

In 2004, we operated through the following businesses:

	•	Product Sales (the Pharmaceuticals Division);
	•	Development Services (the AAI Development Services Division); and
	•	Product Development (Research and Development).

For information about the net revenues, income (loss) from operations and total assets of each segment of our business for each of the last three years, see Note 14 of Notes to Consolidated Financial Statements included in Part II, Item 8 “Financial Statements and Supplementary Data.”

In March 2005, we reorganized our operating structure to reflect our decision to curtail our research and development activities in light of our financial condition. As a result of this reorganization of our operating structure, we currently operate in only two business segments – proprietary pharmaceutical product development and sales through our Pharmaceuticals Division and development services offered to third parties through our AAI Development Services Division.

Overview of Financial Condition

We incurred a substantial net loss and loss from operations for 2004 and the quarter ended December 31, 2004. (See Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations – Overview of Results of Operations.”) In 2005, our results of operations have continued to deteriorate as customer concerns regarding our financial condition have affected sales of our pharmaceutical products and our ability to obtain and maintain development services engagements. As a result of our substantial and recurring operating losses, we believe that we do not have adequate sources of liquidity to fund our operations in the near term unless we obtain additional sources of liquidity. We did not make the $10.5 million scheduled interest payment due on our senior subordinated notes on April 1, 2005 and have discontinued payments under leases for assets not used in operations.

In light of our current financial condition, we believe that our operations can no longer support our existing debt and that we must restructure our debt to levels that are more in line with our operations. Thus, it is highly likely that we will seek relief under chapter 11 of Title 11 of the U.S. Code

2

(the “Bankruptcy Code”) which would substantially dilute and may eliminate the interests of the holders of our common stock. For additional discussion of our financial condition and liquidity, see Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations – Liquidity and Capital Resources.”

Pharmaceuticals Division – Our Product Sales Business

The Pharmaceuticals Division markets and commercializes the pharmaceutical products that we have acquired or developed. In addition, the Pharmaceuticals Division manages the development of our pipeline products, see “Research and Development – Our Internal Product Development Pipeline.” We commercialize products in the pain and critical care therapeutic areas. Our pain products include Duraclon, Drug Enforcement Administration (DEA) Schedule IV products (Darvon/Darvocet) and DEA Schedule II products (Methadone injectable, Roxicodone, Roxanol, and Oramorph SR). Our critical care products are used to treat organ rejection in kidney transplants (azathioprine) and severe asthma (Brethine).

Potential Divestiture of Assets

We have been exploring a potential sale of some or all of the assets of our Pharmaceuticals Division, including the Darvon/Darvocet products, as well as other operating assets. On March 31, 2005, we entered into an exclusivity agreement with a potential purchaser of the assets of our Pharmaceuticals Division to facilitate continued due diligence and negotiation over a potential sale. This written agreement expired on April 22, 2005, though we are continuing to negotiate with this potential purchaser on an exclusive basis. We have not yet reached a definitive agreement with this potential purchaser for the sale of any assets. In addition, we have not determined to sell any material assets, and we plan to continue to operate our Pharmaceuticals Division if we do not complete a sale of its assets. Any sale of some or all of the assets of our Pharmaceuticals Division would likely occur as part of a bankruptcy proceeding, and thus would be subject to the approval of the bankruptcy court and may be subject to the approval of the lenders under our senior credit facilities, the holders of our notes and our stockholders.

Distribution of Pharmaceutical Products

We have contracted with a subsidiary of Cardinal Health, Inc. to provide warehousing, distribution, inventory tracking, customer service, and financial administrative assistance related to our pharmaceutical product distribution program, including management of applicable chargebacks, and accounts receivable collection.

On December 26, 2003, we entered into an agreement with a second subsidiary of Cardinal Health, Inc., effective as of October 1, 2003, to act as our exclusive distributor for our Brethine injectable product for a three-year period.

Manufacturing Capability

We currently manufacture a highly toxic drug product, along with DEA controlled substance products, for ourselves in our manufacturing facility in Wilmington, North Carolina. Although our manufacturing generally covers small volume products, our manufacturing capability has been upgraded to allow commercial volume manufacture of a portion of the Darvon and Darvocet family of products in our own facility. In addition, we operate a 48,000-square-foot

3

sterile manufacturing facility in Charleston, South Carolina where we manufacture sterile, injectable products, including our Methadone injectable product and the vial presentation of our Brethine injectable product.

Marketing and Sales

We initially marketed our pharmaceutical product lines through a contract sales force. In late 2002, we created an internal sales and marketing capability to augment this contract sales force. In connection with our launch of Darvocet A500, we entered into a Service Agreement with Athlon Pharmaceuticals, Inc. pursuant to which representatives of Athlon would promote the sale of our Darvocet A500 product to physicians. We terminated this agreement in June 2004, but it remains the subject of litigation between the parties. (See Part I, Item 3, “Legal Proceedings – Athlon Litigation” below). In the second quarter of 2004, we made a strategic decision to refocus our sales force to the hospital and pain clinic markets following our acquisition of Duraclon, Oramorph SR and a Methadone injectable product. Our sales force was redesigned to provide experienced and knowledgeable professionals to sell our complex, highly technical specialty pharmaceutical products to a sophisticated target market. We believed that this new, narrower focus would create greater efficiencies for our sales team and allow us a forum to discuss the clinical benefits of our products. In the fourth quarter of 2004, we made the decision to eliminate our sales force due to our liquidity issues. We reached the conclusion that we could not afford to build our sales force to a sufficient scale that would be effective in increasing product revenues sufficient to justify the cost of our sales force. As of December 31, 2004, we no longer employed a pharmaceutical products sales force. Instead, we rely on a small commercial group that works at maintaining logistical supply, works with large wholesalers and hospital buying groups, and performs other activities needed to maintain an ongoing pharmaceutical products commercial business.

Our Pharmaceutical Products

We commercialize products in two therapeutic areas: pain management and critical care.

Pain Management Products

Roxicodone, Oramorph SR, Roxanol and Duraclon Product Lines. On December 2, 2003, we acquired a line of pain management products, which treat moderate-to-severe pain, and existing inventory from subsidiaries of Elan. We acquired these product lines, inventory and related intangible assets for $102.5 million, exclusive of transactional costs. These products consist of three brands of DEA Schedule II (CII) pain products — Roxicodone (oxycodone hydrochloride) tablets and immediate release oral solutions, Oramorph SR (morphine sulfate) sustained-release tablets, and Roxanol (morphine sulfate) immediate release oral solutions. We also acquired a non-scheduled pain management product, Duraclon (clonidine hydrochloride) injection, as part of the same transaction. DEA Schedule II pain products are regulated as controlled substances by the U.S. Drug Enforcement Administration. Each of these DEA Schedule II pain products, other than Oramorph SR, is subject to generic competition. Oramorph SR is subject to therapeutic substitution by pharmacists in certain states.

4

Supply of Product. Roxicodone, Oramorph SR, Roxanol and Duraclon are manufactured and supplied by third parties. Duraclon is currently purchased on a purchase order basis from American Pharmaceutical Partners, Inc. Roxicodone, Oramorph SR, and Roxanol are purchased pursuant to a manufacturing agreement between Roxane Laboratories, Inc. (“Roxane”) and Elan Pharma International Limited dated September 28, 2001 (the “Roxane Supply Agreement”). We assumed Elan Pharma International Limited’s rights and obligations under the Roxane Supply Agreement. The term of the Roxane Supply Agreement expires on September 27, 2006. Roxane manufactures the applicable products in its Columbus, Ohio facility.

Darvon and Darvocet. On March 28, 2002, we acquired from Eli Lilly the U.S. rights to the Darvon and Darvocet branded product lines in the U.S. (and the existing inventory of these products). The Darvon and Darvocet products are prescribed for the treatment of mild-to-moderate pain. The acquired products include Darvon (propoxyphene hydrochloride), Darvocet-N (propoxyphene napsylate and acetaminophen), Darvon-N (propoxyphene napsylate) and Darvon Compound-65 (propoxyphene hydrochloride, aspirin, and caffeine).

These product lines have been sold in the U.S. for over 25 years, with the initial marketing of Darvon beginning in 1957. Darvon’s patent exclusivity expired in 1973 and Darvon-N and Darvocet-N’s patent exclusivity expired in 1985. The first generic version of Darvon was introduced in 1973, and by 1985, numerous generic products were being marketed for substitution for Darvon and Darvocet.

We paid $211.4 million in cash, exclusive of transactional costs, for the rights in the U.S. to these products and Eli Lilly’s existing inventory of these products. In addition, we have agreed to pay Eli Lilly royalties upon sales of our future developed improvements to the Darvon and Darvocet products or other products containing the active ingredient propoxyphene and any other pharmaceutical products sold under the name Darvon, Darvocet or certain other trademarks. We agreed to pay royalties for future products during each calendar quarter for a ten-year period beginning upon the product’s commercial introduction, provided that the total net sales of all of these future products, combined with the total net sales of the current Darvon and Darvocet products, exceed $15.0 million in the applicable calendar quarter. Darvocet A500 is the only product we currently sell that could subject us to a royalty payment; however, no royalties were payable for sales made in 2004. Under our agreement with Eli Lilly, we are not required to pay any royalties on the sales of the Darvon and Darvocet products themselves that we acquired from Eli Lilly.

Supply of Product. Until the agreement expired on December 31, 2004, we were party to a manufacturing agreement, as amended, that we entered into with Eli Lilly under which Eli Lilly agreed to supply specified quantities of the acquired products and the bulk active ingredient from and after closing for the then-existing twelve Darvon and Darvocet product presentations (form, dosage and packaging). We purchased these products manufactured by Eli Lilly for a fixed unit cost, subject to a percentage increase on each January 1 plus any increase in Eli Lilly’s cost of raw materials during that year. However, the purchase price for these products was no less than Eli Lilly’s standard cost of manufacturing, which included raw materials, direct labor, and plant overhead attributable to the Darvon and Darvocet products. We are currently manufacturing in our Wilmington, North Carolina facility all of the products previously manufactured by Eli Lilly,

5

except for our Darvocet N 100 product. This product is manufactured by DSM Pharmaceuticals Inc. pursuant to a supply agreement that expires in January 2009.

Darvocet A500. We acquired a product which we subsequently branded as Darvocet A500 from Athlon Pharmaceuticals in July 2003. Darvocet A500 contains 500 mg of acetaminophen, compared to 650 mg in Darvocet-N 100. We received FDA approval of Darvocet A500 on September 10, 2003, launched the product in September 2003 and initiated a national campaign in October 2003. Under the acquisition agreement for this product, we owe Athlon royalties on a quarterly basis until 2023 in an amount equal to 10% of net sales of our Darvocet A500 product and any other combination propoxyphene napsylate and acetaminophen products we may sell in the future.

In connection with the acquisition, we entered a three-year services agreement with Athlon Pharmaceuticals to provide sales support in designated territories throughout the United States for the Darvocet A500 product. After providing notice to Athlon of its material breach under this agreement, we terminated this agreement on June 4, 2004 and initiated litigation. Athlon has brought counterclaims seeking payment of unpaid monthly payments under the terminated contract and additional litigation, now consolidated, with respect to the royalty provisions of the asset purchase agreement pertaining to Darvocet A500. The litigation is continuing. See Part I, Item 3, “Legal Proceedings – Athlon Litigation” below.

Supply of Product. Darvocet A500 is manufactured and supplied by Mikart, Inc. (“Mikart”). Mikart manufactures Darvocet A500 in its Atlanta, Georgia facility. We have entered into an agreement with Mikart to supply us with our requirements for Darvocet A500 for an initial term ending 2013. Thereafter, the agreement with Mikart will continue for successive one-year renewal terms unless terminated by either party as set forth in the agreement. The agreement requires us to make a payment to Mikart if we have not purchased a set amount of Darvocet A500 by September 2006. In the fourth quarter of 2004, we incurred a purchase commitment charge of $11.7 million in connection with the establishment of a reserve related to this minimum purchase requirement. We are currently negotiating with Mikart to extend the term of the agreement by an additional multi-year period, and to amend our obligation to purchase the minimum level of Darvocet A500 products to include additional products to be manufactured by Mikart for us under this agreement and applied against our minimum purchase requirement. If we are successful in amending the agreement on this basis, the reserve and corresponding charge may be reversed in a subsequent period. We cannot provide any assurance, however, that we will be successful in amending the agreement on any terms.

Methadone Hydrochloride Injection. In April 2003, we acquired exclusive rights to a parenterally administered methadone injectable product, formerly branded as Dolophine Hydrochloride Injection, from Roxane. This product is indicated for the treatment of moderate-to-severe pain not responsive to non-narcotic analgesics, and for use in temporary treatment of opioid dependence in patients unable to take oral medication.

We manufacture this product at our facility in Charleston, South Carolina.

6

Critical Care Products

Brethine. On December 13, 2001, we acquired the U.S. rights to the Brethine branded product line from Novartis Pharmaceuticals Corporation and Novartis Corporation for $26.6 million in cash, exclusive of transactional costs. On April 19, 2004, the FDA approved our Supplemental New Drug Application for a vial presentation of the injectable form of this product, which replaced our former ampul presentation. On November 1, 2004, we launched our Brethine vial presentation into the U.S. market.

IMPAX Laboratories has been marketing a generic version of the oral form of Brethine since July 2001. Multiple generic versions of the injectable form of this drug, including a vial presentation, were approved starting in May 2004.

Supply of Product. Until the agreement expired on December 13, 2004, we were party to an interim supply agreement with Novartis providing for manufacture and packaging of the oral and injectable form of Brethine for sale by us in the U.S. Under this supply agreement, we purchased the products for a fixed unit cost that was subject to an annual price adjustment on January 1, 2003 and January 1, 2004 tied to the Consumer Price Index. We have transferred the Brethine vial manufacturing processes to our Charleston, South Carolina facility.

Azathioprine. In 2003, we received FDA approval to market three internally developed line extensions of additional strengths to our current 50 mg generic azathioprine tablet product: 25 mg, 75 mg and 100 mg tablets. We began selling the 75 mg and 100 mg products in the first quarter of 2003. In November 2003, we granted Salix Pharmaceuticals an exclusive license to market the 25 mg, 75 mg, and 100 mg strengths of Azasan (azathioprine) and we licensed our Azasan trademark to Salix. Under the agreement with Salix, we receive royalties on net sales. Salix has the right to terminate this agreement at any time with six months’ written notice after October 31, 2006. We entered into a three-year supply agreement with Salix to continue to manufacture these products and supply all of Salix’s needs. We continue to manufacture and sell our 50 mg azathioprine tablet product as a generic product.

Product Disposition and Discontinuance During 2004

M.V.I. and Aquasol. On August 17, 2001, we acquired the M.V.I. and Aquasol branded lines of critical care injectable and oral nutritional products from AstraZeneca for $52.5 million, exclusive of transactional costs, paid at closing, plus additional consideration described below. Our M.V.I. and Aquasol product line acquisition agreement was amended on July 22, 2003. As amended, it provided for two $1.0 million guaranteed payments, which were made in August 2002 and 2003, eliminated a contingent payment of $2.0 million that was potentially due in August 2003 under the original agreement, and provided for a future contingent payment of $43.5 million potentially due in August 2004, depending on the status of certain reformulation activities being carried out by the seller and regulatory approval of the reformulation by the FDA. The amount of the $43.5 million contingent payment was to be reduced by $1 million per month if the conditions for the contingent payment had not occurred by December 31, 2002. The conditions for the contingent payment were not met by the required date, so the amount of the contingent payment had decreased by $12.0 million by the end of December 2003. Such conditions were satisfied in January and February 2004, fixing the liability at $31.5 million,

7

which was charged to operations and recorded as a liability on our consolidated financial statements in the first quarter of 2004. Also on July 22, 2003, the M.V.I. supply agreement with the seller was extended through 2008, subject to early termination rights by us on six months’ notice given at any time, and by the supplier on twenty-four months’ notice given at any time on or after August 17, 2004. The M.V.I. and Aquasol product lines did not have separable assets and liabilities associated with them other than inventory; therefore, we allocated the remaining purchase price to acquired identifiable intangible assets.

On April 26, 2004, we sold our M.V.I. and Aquasol product lines to Mayne Pharma (USA) Inc. for $105 million, subject to adjustments based on inventory levels at closing and other post-closing obligations. Of that amount, $10 million was held in escrow to satisfy our post-closing obligations under the agreement. In September 2004, approximately $1.6 million of this escrowed amount was paid to us. We do not anticipate receiving any additional payments out of this escrow. At the closing of the transaction, we paid to AstraZeneca AB the $31.5 million payment due in August 2004, which was discounted to approximately $31.0 million. This payment represented a payment upon FDA approval of the reformulated product under the terms of the amended purchase agreement with AstraZeneca.

Calcitriol. In February 2002, we purchased a calcitriol product from Aesgen, Inc. for payments of $1.0 million in cash and additional contingent milestone payments of up to $1.5 million. Calcitriol is a drug used primarily to treat chronic kidney dialysis patients with abnormally low levels of calcium in their blood. In 2003, the prerequisite for payment of $500,000 of such contingent milestones occurred and such payment was made to Aesgen. The prerequisites for payment of the remaining $1.0 million of such contingent milestones were not met.

We also sold calcitriol under an exclusive manufacturing and co-promotion agreement with Sicor Pharmaceuticals, Inc. pursuant to which we acquired U.S. marketing rights to, and sold, Sicor Pharmaceuticals’ calcitriol product under their regulatory approval. We amended the 2002 calcitriol injection acquisition agreement with Aesgen in 2003 to provide for royalty payments to Aesgen on the gross margin we realized from our sales of the calcitriol product marketed under Sicor’s regulatory approval and to provide for potential payments to Aesgen in connection with a reacquisition by Sicor or an assignment to a third party of the U.S. marketing rights to calcitriol injection. On December 23, 2004, Sicor Pharmaceuticals reacquired its U.S. marketing rights to calcitriol injection, pursuant to the termination of the manufacturing and co-promotion agreement discussed above. In connection with such termination, Sicor paid us $3.5 million. We no longer commercialize calcitriol.

AAI Development Services — Our Development Services Business

AAI Development Services offers a comprehensive range of pharmaceutical product development services to our customers, who are located worldwide. These services include formulation development, analytical, microbiological, bioanalytical and stability testing services, production scale-up, biotechnology analysis, human clinical trials, regulatory and quality consulting, and manufacturing. These services generally are provided on a fee-for-service basis.

AAI Development Services provides its services, both individually and in an integrated fashion, to:

8

	•	our customers, to help them develop, optimize, control, and supply their drug products;
	•	our Pharmaceuticals Division, to support product life cycle management and commercial manufacture of the acquired drug products; and
	•	our research and development activities, by executing on defined project plans and managing our portfolio of patents and drug-delivery technologies.

	Since our founding in 1979, we have contributed to the submission, approval or continued marketing of many client products, encompassing a wide range of therapeutic categories and technologies. We believe that our ability to offer an extensive portfolio of high quality drug development and support services enables us to effectively compete as pharmaceutical and biotechnology companies look for a mixture of stand-alone and integrated drug development solutions that offer cost-effective results on an accelerated basis.
	We have a strong base of resources, expertise, and ideas that allows us to develop and improve drug products and carry out product life cycle management activities both for our customers and ourselves. Our expertise covers many therapeutic categories and types of pharmaceutical products.
	We focus on our customers’ individual needs when marketing our services, often placing our technical personnel with our clients’ development teams to participate in planning meetings for the development or improvement of a product. We assign our sales and technical personnel as contacts for our larger clients, understanding that technical personnel may be better able to identify the full scope of our client’s needs and suggest innovative approaches.
	Generally, AAI Development Services’ fee-for-service contracts are terminable by the client upon notice of 30 days or less. Although the contracts typically permit payment of certain fees for winding down a project or for work incurred to date, the loss of a large contract or the loss of multiple contracts could adversely affect our future revenue and profitability in our Development Services business. Contracts may be terminated for a variety of reasons, including the client’s decision to stop a particular study, the failure of product prototypes to satisfy safety requirements, and unexpected or undesired results of product testing.
	Pharmaceutical Services
	AAI Development Services provides a variety of pharmaceutical services to its customers, including drug formulation development and small scale manufacturing, as well as storage and distribution of clinical trial supplies. The services are organized to help clients from the pre-clinical to post-marketing stages.
	Formulation Development Services. AAI Development Services provides integrated formulation development services for customers’ pharmaceutical products to develop safe and stable products with desired characteristics. AAI Development Services provides services during each phase of the drug development process, from new compounds to modifications of existing products. These formulation development projects may last for a short duration or for several years.

9

	The formulation development group also manages our portfolio of intellectual property assets, including patents and technologies, which are available for licensing to third parties or incorporation into our existing product pipeline, see “Research and Development – Our Drug-Delivery Technologies.”
	Manufacture of Clinical Trial Supplies and Third Party Pharmaceutical Products. AAI Development Services manufactures clinical trials materials for Phase I through IV drug-product clinical trials. It has experience in manufacturing tablets, capsules, liquids, and suspensions. Outsourcing of clinical supply manufacturing is particularly attractive to pharmaceutical companies that maintain large, commercial-quantity, batch facilities, where clinical supply manufacturing would divert resources from revenue-producing manufacturing. AAI Development Services has a dedicated 25,000 square foot facility in Wilmington, North Carolina and another facility in Neu-Ulm, Germany to distribute and track clinical trial materials used in clinical studies. Additionally, it has the capacity for controlled substance storage and handling. AAI Development Services provides its clients with assistance in scaling up production of clinical supply quantities to commercial quantity manufacturing and provides small batch commercial manufacturing capabilities.
	AAI Development Services also manufactures certain drugs for commercial sale by third-party pharmaceutical company clients. These products range from small volume, high-potency or high-toxicity drug products, to larger scale oral solid products. Oral products are manufactured in our Wilmington, North Carolina facility, while sterile injectable products are manufactured in our Charleston, South Carolina facility.
	Analytical Services
	AAI Development Services provides a wide variety of analytical services, as well as services pertaining to method development and validation, drug product and active pharmaceutical ingredient characterization and control, microbiological support, stability storage and studies, technical support, and problem solving. Our analytical services include:

	•	Method development and validation;
	•	Product characterization;
	•	Raw materials and product release testing; and
	•	Stability studies.

Biopharmaceutical Services

AAI Development Services integrates a Phase I clinical study capability with bioanalytical and biotechnology expertise to provide biopharmaceutical services to its customers. The analysis of drugs, metabolites, and endogenous compounds in biological samples is a core service. Our biopharmaceutical services include:

	•	Phase I clinical services from our 88-bed Phase I clinical trial facility located in Research Triangle Park, North Carolina, and a 72-bed facility in Neu-Ulm, Germany;
	•	Microbiological testing;
	•	Bioanalytical testing; and

10

•

Biotechnology analysis.

Phase I to IV Clinical Services

AAI Development Services provides a broad range of Phase I through IV clinical services to customers in the pharmaceutical, biotechnology, and medical device industries for assistance in the drug development and regulatory approval process in North America and Europe. The clinical services include clinical protocol and program development, global clinical strategy consulting, investigator/site management, clinical trial management and monitoring, Project Management, site selection, medical affairs (including safety surveillance, pharmacovigilance and serious adverse event management), data management, and biostatistics.

Regulatory and Other Consulting Services

AAI Development Services provides consulting services with respect to regulatory affairs, quality compliance, and process validations. It assists in the preparation of regulatory submissions for drugs, devices, and biologics, audits clients’ vendors and client operations, conducts seminars, provides training courses, and advises clients on applicable regulatory requirements. AAI Development Services also assists clients in designing development programs for new or existing drugs intended to be marketed in the United States and Europe.

Research and Development

Our research and development expenditures for 2005 will be significantly below historical trends due to our financial condition. In March 2005, we reorganized our research and development group to maximize efficiency, given the limited resources available to us. Our research and development efforts are currently focused on three products in development. The oversight of the development efforts on our pipeline products is conducted by a group within our Pharmaceuticals Division to ensure the proper alignment of development efforts and commercial opportunities. The management of our intellectual property assets, including our drug delivery technologies and patents, is conducted by the Formulations Development Services group in our AAI Development Services Division.

Our Drug-Delivery Technologies

Our portfolio of internally developed and in-licensed drug-delivery technologies includes:

	•	ProCore — a patented technology for controlled release of a drug incorporated into a two-layer coated pellet. The first layer allows for control of the lag time before an active agent begins its release while the second layer controls the rate of release, and thus the duration of the sustained release effect for the product.
	•	ProSorb — a technology designed to accelerate absorption rates and potentially minimize inter- or intra-patient variability. It generally permits weakly acidic compounds to exhibit a shorter onset of action relative to conventional dosage forms. The concept is that acidic drugs with the benefit of the technology form a dispersion pattern upon release in the stomach that allows for faster stomach clearance and more rapid absorption in the intestinal tract. ProSorb is a broad-based technology primarily used with liquid or

11

encapsulated drug products. The application of this technology to diclofenac, a non-steroidal anti-inflammatory drug, has resulted in our proprietary Lynxorb product candidate, which is discussed below.

	•	ProLonic AQ — a drug-delivery technology specifically designed to release an active agent in the colon. This technology can be incorporated into a tablet, a pellet, or a capsule dosage form and uses conventional manufacturing equipment and aqueous coating processes. The advantage represented by this technology is the ability to control the location and timing of release and eliminate the need for solvent-based safety concerns.
	•	ProSLO and ProSLO II — an osmotic technology designed to produce controlled release product therapy with either a single drug or a combination of drugs. Osmotic action is the natural movement of an aqueous solution through a membrane and is used to make oral drug administration more accurate, precise, and convenient. This technology allows for an immediate release component in the outside layer of a laser drilled tablet. This facilitates two release patterns for a single drug (i.e., bi-phasic) or a combination of multiple active ingredients with different release requirements. The advantages over existing technologies are its easy scalability, the ability to use it with numerous active ingredients, the ability to create both a long- and short-acting drug combination, and its ability to handle what normally are reasonably insoluble active ingredients.

We own the ProCore, ProSorb, and Prolonic AQ technologies. The ProSLO and ProSLO II technologies are available for use by us and our clients throughout the world, except Latin America, through an agreement with Osmotica Corporation. We have entered into a Cooperative Venture Agreement with Osmotica Corporation to develop, manufacture, and license various new drug products with third party organizations. This agreement enables us to develop mutually acceptable new drug products or improve the characteristics of mutually acceptable products and compounds utilizing patents, patent applications, and know-how associated with pharmaceutical formulation technologies for such products.

On January 15, 2004, we announced that Aventis submitted an NDA to the FDA for Allegra-D 24-hour tablets. This is a fexofenadine/pseudoephedrine formulation developed under our agreement with Osmotica with a patented extended release drug-delivery technology, ProSLO II. This product was approved by the FDA on October 19, 2004. We received a milestone payment from Aventis for that approval and expect to receive royalties on sales of the product in 2005.

Our Internal Product Development Pipeline

In 2004, we worked on three development projects:

	•	A modified release Darvocet product. We have discussed our development plan with the FDA and, based on FDA input, we are implementing a development plan which we believe will be appropriate for filing our regulatory submission. We hope to complete pivotal trials for this product in early 2006.
	•	Lynxorb - a formulation of diclofenac that utilizes our proprietary ProSorb technology to enhance the amount and speed of absorption of this potent inhibitor of COX1 and COX2

12

		enzymes. We have submitted our pivotal trial protocol to the FDA for comment. Pivotal trials for this product may be delayed due to budget constraints and liquidity concerns.
	•	An aaiPharma formulation of a generic proton pump inhibitor has made significant progress in achieving the desired pharmacokinetic profile. We believe further development of this product will be delayed due to budget constraints and liquidity concerns.

For fiscal years 2004, 2003 and 2002, our expenditures on research and development were $16.3 million, $21.8 million and $20.9 million, respectively. Due to liquidity constraints, we anticipate that 2005 expenditures on research and development will significantly decline. We can provide no assurances that we will be able to fund further research and development activities on these or any other projects in 2005, or at all. The only product under active development is the Darvocet line extension.

Information Technology

Significant upgrades to our core information systems were completed during 2004. These upgrades will help improve on-going compliance with legal requirements and expand our capabilities to automate data capture. New systems were placed into operational use in 2004 to handle increased data volume and to ensure compliance with FDA regulations for the clinical trials work provided by AAI Development Services. The end of 2004 marked the completion of a three-year information technology cycle where all personal computers and core infrastructure were replaced. Our customized data management system connects analytical instruments with multiple software architectures permitting automated data capture. We believe that information technology enables us to expedite the development process by designing innovative services for individual client needs, providing project execution, monitoring and control capabilities that exceed a client’s internal capabilities, streamlining and enhancing data presentation to the FDA and improving our own internal operational productivity, while helping to maintain quality.

Customers

The Pharmaceuticals Division’s customers are primarily large well-established pharmaceutical wholesalers. Cardinal Health, Inc., AmerisourceBergen Corporation and McKesson Corporation accounted for approximately 7.3%, 9.4% and 13.1% of our 2004 consolidated net revenues, respectively, and 20.2%, 26.0% and 36.3%, respectively, of our Pharmaceuticals Division net revenues. As is customary in the pharmaceutical industry, we accept returns of products we have sold as the products near their expiration date.

Significant research and development projects have a defined cycle, and accordingly, the customers of our AAI Development Services Division and customers for our research and development activities change from year to year. Because of the project nature of engagements in these business segments, large customers may represent a significant portion of the business in one period but not subsequent periods. We have experienced concentration in these areas of our business in the past, and do not believe that this is unusual for companies which operate in this market.

13

Backlog

Our order backlog consists of anticipated net revenues from signed fee-for-service contracts for which services have not been completed. Once contracted work begins, net revenues are recognized as the service is performed. The order backlog does not include anticipated net revenues for work performed for internal clients or for any variable-priced contracts. During the course of a project, a client may substantially adjust the requested scope of services and corresponding adjustments are made. Our order backlog also includes orders for pharmaceutical products that have been ordered by our customers, but have not yet been shipped.

We believe that our order backlog as of any date is not a complete predictor of future results due to the variability and short duration of many of our development services contracts. The backlog can also be affected by adjustments in the scope of contracted projects. At December 31, 2004 and 2003, our order backlog was approximately $47.8 million and $52.0 million, respectively. We do not expect to fill approximately $11.2 million of the 2004 amount by December 31, 2005, which is related to longer term clinical trials and stability projects. Included in the backlog total at December 31, 2004 is $3.1 million for pharmaceutical products ordered but not yet shipped.

Competition

We compete with companies and organizations in multiple segments of the pharmaceutical industry. The branded drug products of our Pharmaceuticals Division are subject to competition from the branded and generic products of other pharmaceutical companies, ranging from small specialty pharmaceutical companies to large pharmaceutical companies.

The following tables illustrate the products that compete with the products we sell:

Our Branded Products

14

Our Generic Product

We do not believe that there are any products that are competitive with our Duraclon product. In addition to the competitive products listed above, additional competitive products may be introduced in the future.

Our AAI Development Services Division and research and development activities compete primarily with in-house research, development, quality control, and other support service departments of pharmaceutical and biotechnology companies, as well as university research laboratories and other contract research organizations. Some of our competitors, however, may have significantly greater resources than we do. Competitive factors generally include reliability, turn-around time, reputation for innovative and quality science, capacity to perform numerous required services, financial viability, and price.

Government Regulation

The services that we perform and the pharmaceutical products that we develop, manufacture, and sell are subject to various rigorous regulatory requirements designed to ensure the safety, effectiveness, quality, and integrity of pharmaceutical products, primarily under the Federal Food, Drug, and Cosmetic Act, including current Good Manufacturing Practice regulations. These regulations are commonly referred to as the cGMP regulations and are administered by the FDA in accordance with current industry standards. Our services and development efforts performed outside the U.S. and products intended to be sold outside the U.S. are also subject to additional foreign regulatory requirements and government agencies.

U.S. laws and federal regulations apply to all phases of investigational and commercial development (i.e. manufacturing, testing, promotion and distribution of drugs, including with respect to our personnel, record keeping, facilities, equipment, control of materials, processes, laboratories, packaging, labeling, storage, and advertising). If we fail to comply with these laws and regulations, our drugs, drug improvements, and product line extensions will not be approved by the FDA or will be withdrawn from the market and the data we collect may be out of specification and not acceptable to the FDA requirements, which may result in us not being

15

permitted to market our products. Additionally, we could be subject to significant monetary fines, recalls and seizures of products, closing of our facilities, revocation of drug approvals previously granted to us, and criminal prosecution. Any of these regulatory actions could materially and adversely affect our business, financial condition, and results of operations.

To help assure our compliance with applicable laws and regulations, we have quality assurance controls in place at our facilities and we use FDA regulations and guidelines, as well as applicable international standards, as a basis for our quality policies and standard operating procedures. We regularly audit test data, inspect our facilities, and revise our standard operating procedures to meet current cGMPs. In addition, we maintain a system for monitoring product-related complaints for all of our commercial products.

The balance of adhering to FDA compliance while bringing products to market requires us to continuously improve our operating standards in order to reduce the possible risk of FDA actions. In the event of any such action of a material nature, the resulting restrictions on our business could materially and adversely affect our business, financial condition, and operating results.

All of our drugs, investigational and commercial, must be manufactured in conformity with International Conference on Harmonization, or ICH, guidances, cGMP regulations, and FDA guidances and guidelines. Drug products subject to an approved FDA-application must be manufactured, processed, packaged, held, and labeled in accordance with information contained in the application. Modifications, enhancements, or changes in manufacturing sites of approved products are in many cases subject to additional FDA inspections and supplemental approvals to the existing application. The circumstances requiring inspections and supplemental filings may require a lengthy application process. Our facilities, including the facilities used in our development services business and those of our third-party manufacturers, are periodically subject to inspection by the FDA and other governmental agencies. If such inspections prove unsatisfactory, the operations at these facilities could be interrupted or halted for lengthy periods of time.

Failure to comply with FDA or other governmental regulations can result in warning letters. If those warning letters are not adequately addressed, further actions may lead to fines, unanticipated compliance expenditures, recall or seizure of products, or total or partial suspension of production or distribution. For drugs under FDA review, failure to be compliant at manufacturing facilities could stop the FDA’s review of our drug approval applications that could, in certain circumstances, extend to the termination of ongoing research, disqualification of data for submission to regulatory authorities, enforcement actions, injunctions, and criminal prosecution. Under certain circumstances, the FDA also has the authority to revoke previously granted drug approvals. Although we have instituted internal compliance programs that consistently comply with cGMPs through strong training and corporate quality oversight, we are cognizant that if these programs do not meet regulatory agency standards or if compliance is deemed deficient in any significant way, it could have a material adverse effect on us, our third party manufacturers, and our vendors. Most of our vendors are subject to similar regulations and periodic inspections.

16

Some of our development and testing activities for our customers, and the manufacture, development, and testing of the line of pain management products (the “New Pain Products”) that we acquired from subsidiaries of Elan, our Darvon and Darvocet products, and our methadone hydrochloride product, are subject to the Controlled Substances Act, administered by the Drug Enforcement Administration, which strictly regulates all narcotic and habit-forming substances. We maintain separate, restricted-access facilities and heightened control procedures for projects involving such substances due to the level of security and other controls required by the DEA.

Our business also involves the controlled storage, use, and disposal of hazardous materials and biological hazardous materials. We are subject to numerous federal, state, local, and foreign environmental regulations governing the use, storage, handling, and disposal of these materials. Although we believe that our safety procedures for handling and disposing of these hazardous materials comply in all material respects with the standards prescribed by law and regulation in each of our locations, the risk of accidental contamination or injury from hazardous materials cannot be completely eliminated. We maintain liability insurance for some environmental risks that our management believes to be appropriate and in accordance with industry practice. However, we may not be able to maintain this insurance in the future on acceptable terms. In the event of an accident, we could be held liable for damages that are in excess or outside of the scope of our insurance coverage or that deplete all or a significant portion of our resources.

We are also governed by federal, state and local laws of general applicability, such as laws regulating intellectual property, including patents and trademarks, working conditions, equal employment opportunity, and environmental protection.

In connection with our activities outside the U.S., we also are subject to foreign regulatory requirements governing the testing, approval, manufacture, labeling, marketing, and sale of pharmaceutical products, which requirements vary from country to country. Whether or not FDA approval has been obtained for a product, approval by comparable regulatory authorities of foreign countries must be obtained prior to marketing the product in those countries. For example, some of our foreign operations are subject to regulations by the European Medicines Evaluations Agency and the U.K. Medicines and Healthcare products Regulatory Agency. The approval process may be more or less rigorous from country to country, and the time required for approval may be longer or shorter than that required in the U.S. Therefore pharmaceutical product approval and policies for pricing required for marketing will vary from country to country due to different regulations and policies required by each.

The Drug Development Regulatory Process

New Drug Approval Process. FDA approval is required before any new drug can be marketed and sold in the U.S. This approval is obtained through the new drug application, or NDA, process, which involves the submission to the FDA of complete pre-clinical data about new compounds and their characteristics, clinical data obtained from studies in humans showing the safety and effectiveness of the drug for the proposed therapeutic use, and chemistry, manufacturing, and controls data documenting how the drug is made and manufacturing operations are controlled.

17

Before introducing a new drug into humans, stringent government requirements for pre-clinical data must be satisfied. The pre-clinical data is obtained from laboratory studies, and tests performed on animals, which are submitted to the FDA in an investigational new drug application, or an IND. The pre-clinical data must provide an adequate basis for evaluating both the safety and the scientific rationale for the initiation of clinical trials of the new drug in humans. Pursuant to the IND, the new drug is tested in humans for safety, adverse effects, dosage, tolerance absorption, metabolism, excretion and other elements of clinical pharmacology, and for effectiveness for the proposed therapeutic use.

Clinical trials are conducted in three sequential phases (i.e., Phase I, Phase II, and Phase III). The clinical development plan or the process of completing clinical trials during the investigational period for a new drug may take several years and require the expenditure of substantial operational and financial resources. Phase I clinical trials frequently begin with the initial introduction of the investigational drug product into healthy humans and test primarily for safety. Phase II clinical trials typically involve a small sample of the intended patient population to assess the efficacy of the investigational drug product for a specific indication, to determine dose tolerance and the optimal dose range, and to gather additional information relating to safety and potential adverse effects. Phase III clinical trials are studies with a statistically qualified larger study population that compares the active drug product against a placebo. These studies, conducted in a randomized group where the drug and placebo are typically blinded from the physician and patient, further evaluate clinical safety and efficacy at different study sites to determine the overall risk-benefit ratio of the drug and provide an adequate basis for product labeling.

Each clinical trial is conducted in accordance with rules, or protocols, that are developed to detail the objectives of the study, including methods to monitor safety and efficacy and the precise criteria to be evaluated. These protocols must be submitted to the FDA as part of the IND. In some cases, the FDA allows a company to rely on data developed in foreign countries, or previously published data, which eliminates the need to independently repeat some or all of the studies.

Once sufficient data have been developed pursuant to the IND, the NDA is submitted to the FDA to request approval to market the new drug. Preparing an NDA involves substantial data collection, verification and analysis, and expense, and there is no assurance that FDA approval of an NDA can be obtained on a timely basis, if at all. The approval process is affected by a number of factors, primarily the risks and benefits demonstrated in clinical trials as well as the severity of the disease and the availability of alternative treatments. The FDA might not approve an NDA if the regulatory criteria are not satisfied or, alternatively, may require additional studies to enhance the overall risk-benefit ratio prior to an approval action.

Referencing and Relying on New Drug Applications. With respect to the branded pharmaceutical products (e.g., Darvon and Darvocet) that we have acquired, we are often able to reference the original NDA along with the marketing rights to the products. As a result, when improving these products or developing product line extensions, we are permitted to file a supplemental NDA, or a new drug application known as a 505(b)(2) NDA, that directly cross references all of the data in the original application. This provision in the federal Food, Drug, and Cosmetic Act allows us to shorten our development process for improvements and line extensions. For example, we may

18

be able to reduce the number of clinical trials in a clinical development plan with less extensive, less time-consuming, and less costly Phase II and Phase III testing, with respect to any new products that we may select to develop.

Similarly, a 505(b)(2) application allows us to cross reference NDAs, or information therein, that we do not own and are not authorized to reference directly. The 505(b)(2) NDA may, in certain cases, permit us to meet NDA approval requirements with less original scientific data than would normally be required, and may allow us to begin drug development in a later phase, so as to reduce the time and expense involved in any particular phase, for any new products we select to develop. Applications under 505(b)(2) are subject to certain patent and non-patent exclusivity rights applicable to the NDAs on which they rely, if such rights remain in effect when such applications are submitted. If we are unable to proceed with anticipated 505(b)(2) applications for any of the products that we are developing, our FDA approval costs will increase.

Abbreviated New Drug Application Process for Generic Products. A generic drug contains the same active ingredient as a specified brand name drug and usually can be substituted for the brand name drug by the pharmacist. FDA approval is required before a generic drug can be marketed. Approval of a generic drug is obtained through the filing of an abbreviated new drug application, or an ANDA, under section 505(j) of the Food, Drug, and Cosmetic Act. Submission and approval of an ANDA is subject to certain patent and non-patent exclusivity rights applicable to the brand name drug, if such rights remain in effect when the ANDA is submitted. When processing an ANDA, the FDA waives the requirement of conducting full clinical studies provided that the drug is proven bioequivalent to the reference listed drug (i.e., usually the applicant of the NDA) in a Phase I study conducted in a small number of healthy volunteers. Bioavailability relates to the rate and extent of absorption and levels of concentration of a drug active ingredient in the blood stream needed to produce a therapeutic effect. Bioequivalence compares the bioavailability of one drug with another that contains the same active ingredient, and when established, indicates that the rate and extent of absorption and levels of concentration of a generic drug in the body are the same as the previously approved brand name drug. An ANDA may be submitted for a drug on the basis that it is the equivalent to a previously approved drug or, in the case of a new dosage form or other close variant, is suitable for use under the conditions specified.

The timing of final FDA approval of ANDAs depends on a variety of factors, including whether the applicant challenges any listed patents for the brand-name drug and whether the brand-name manufacturer is entitled to one or more non-patent statutory exclusivity periods, during which the FDA is prohibited from accepting or approving applications for generic drugs.

Under section 505(j), the FDA may impose debarment and other penalties on individuals and companies that commit certain illegal acts relating to the generic drug approval process. In some situations, the FDA is required not to accept or review ANDAs for a period of up to three years from a company or an individual that has committed certain violations. The FDA may temporarily deny approval of ANDAs during the investigation of certain violations that could lead to debarment and also, in more limited circumstances, suspend the marketing of approved generic drugs by the affected company. The FDA also may impose civil penalties and withdraw previously approved ANDAs. Neither we nor any of our employees have ever been the subject of debarment procedures.

19

Manufacturing Requirements. Before approving a drug, the FDA also requires that our procedures and operations conform to cGMP regulations, ICH guidances and manufacturing guidelines and guidances published by the FDA. We must be in compliance with all of the regulatory and quality regulations at all times during the manufacture of our products. To help insure compliance with the regulatory and quality regulations, we must continue to spend time, money, and effort in the areas of production and quality control to ensure full technical compliance. If the FDA believes a company is not in compliance with its regulations, it may withhold new drug approvals, as well as approvals for supplemental changes to existing approvals, preventing the company from exporting its products. It may also classify the company as an unacceptable supplier, thereby disqualifying the company from selling products to federal agencies. We believe we are currently in compliance with the cGMP regulations.

Post-approval Requirements. After initial FDA approval for the marketing of a drug has been obtained, further studies, including Phase IV studies, typically regarded as post-marketing studies, may be required to provide additional data on safety or effectiveness. Also, the FDA requires post-marketing reporting to monitor the adverse effects of the drug. Results of post-marketing programs may limit or expand the further marketing of the drug. Further, if there are any modifications to the drug, including changes in indication, manufacturing process, or manufacturing facility, a supplemental application seeking approval of the modifications must be submitted to the FDA or other regulatory authority. Prospectively, the FDA regulates our post-approval promotional labeling and advertising activities to assure that such activities are being conducted in conformity with statutory and regulatory requirements.

Health Care Fraud and Abuse Laws

Federal and state health care fraud and abuse laws have been applied to restrict certain marketing practices in the pharmaceutical industry in recent years. These laws include antikickback statutes and false claims statutes. The federal health care program antikickback statute makes it illegal for anyone to knowingly and willfully make or receive “kickbacks” in return for any health care item or service reimbursed under any federally financed healthcare program. This statute applies to arrangements between pharmaceutical companies and the persons to whom they market, promote, sell, and distribute their products. In 2003, the Office of the Inspector General of the Department of Health and Human Services issued a “Compliance Program Guidance for Pharmaceutical Manufacturers” describing pharmaceutical companies’ activities that may violate the statute. There are a number of exemptions and safe harbors protecting certain common marketing activities from prosecution. These include exemptions or safe harbors for product discounts, payments to employees, personal services contracts, warranties, and administrative fees paid to group purchasing organizations. These exemptions and safe harbors, however, are drawn narrowly.

Federal false claims laws prohibit any person from knowingly making a false claim to the federal government for payment. Recently, several pharmaceutical companies have been investigated or prosecuted under these laws, even though they did not submit claims to government healthcare programs. The prosecutors alleged that they were inflating drug prices they report to pricing services, which are in turn used by the government to set Medicare and Medicaid reimbursement rates. Pharmaceutical companies also have been prosecuted under these laws for allegedly

20

providing free products to customers with the expectation that the customers would seek reimbursement under federal programs for the products.

Additionally, the majority of states have laws similar to the federal antikickback law and false claims laws. Sanctions under these federal and state laws include monetary penalties, exclusion from reimbursement for products under government programs, criminal fines, and imprisonment.

We have internal policies and practices requiring compliance with the health care fraud and abuse laws and false claims laws. Because of the breadth of these laws and the narrowness of the safe harbors, however, it is possible that some of our business practices could be subject to challenge under one or more of these laws, which could have a material adverse effect on our business, financial condition, and results of operations.

Employees

At December 31, 2004, we had 924 full-time equivalent employees, a material reduction from the approximate 1,300 employees at December 31, 2003. At March 31, 2005, we had 855 full time equivalent employees. The decline in the number of employees resulted both from reductions in force and voluntary attrition of employees who were not replaced. While we believe that our relations with our employees are good, our uncertain financial condition has resulted in the loss of a significant number of employees at all levels, including management. None of our employees in the U.S. are represented by a union. European laws provide certain representative rights to our employees in those jurisdictions.

Our continued performance depends on our ability to attract and retain qualified professional, scientific, and technical staff. The level of competition among employers for these skilled personnel is high. We have experienced difficulty in attracting and retaining qualified staff for certain positions in our Phase II and III U.S. operations, where high turnover is an industry-wide problem, and in other skilled positions. It is possible that as competition for skilled employees increases at our other operations or locations, we could experience similar problems there as well. Our liquidity issues and uncertain financial condition, our potential bankruptcy filing, our potential sale of material assets, declines in our stock price, and reductions in force have also decreased, and may continue to decrease, our ability to attract and retain employees.

Intellectual Property

Our ability to successfully commercialize new branded products or technologies is significantly enhanced by our ability to secure and enforce strong intellectual property rights — generally patents — covering these products and technologies, and to avoid infringement of valid third-party patents. We intend to seek patent protection in the United States and selected foreign countries and to vigorously prosecute patent infringements, as we deem appropriate. We currently own patents issued by the U.S. Patent and Trademark Office, and have additional patent applications filed and pending with the U.S. Patent and Trademark Office. Additionally, we have assigned or transferred six of our U.S. patents, one Canadian patent and three of our invention disclosure memoranda to third parties for value.

21

Our patents cover proprietary processes and techniques, or formulation technologies, that may be applied to both new and existing products and chemical compounds. Our patents also cover new chemical entities or compounds, pharmaceutical formulations, and methods of using certain compounds.

We are actively pursuing patent infringement against Kremers Urban Development Co., Schwarz Pharma Inc. and their related companies to protect our rights under two of our patents with respect to omeprazole. During the first twenty-two months of sales, the defendants in this action have publicly confirmed approximately $1.3 billion in sales from the product that we believe is infringing our patents. Litigation involves a high degree of uncertainty as to outcomes, and we cannot predict the outcome of our infringement claims. The defendants have also asserted various counter claims against us, including violations of antitrust laws. See “Item 3. Legal Proceedings – Patent Litigation” for more information on this proceeding.

We have a license in the U.S. and some other countries to use the patents, patent applications, and know-how associated with certain pharmaceutical formulation technologies for mutually acceptable drug candidates. The ProSLO and ProSLO II technologies are licensed from Osmotica Corporation. Like our own formulation technologies mentioned above, these technologies may be used to develop mutually acceptable new drug products or improve the characteristics of mutually acceptable existing products and compounds.

In addition to our patents, we rely upon trade secrets and unpatented proprietary know-how where we believe public disclosures would not be in our best strategic interest. We seek to protect these assets as permitted under state or federal law and by requiring our employees, consultants, licensees, and other companies to enter into confidentiality and nondisclosure agreements and, when appropriate, assignment of invention agreements.

In the case of strategic partnerships or collaborative arrangements requiring the sharing of data, our policy is to disclose to our partner only such data as is relevant to the partnership or as required under the arrangement during its term.

Item 2. Properties

Our principal executive offices are located in Wilmington, North Carolina, in a 73,000 square foot owned facility. Our primary U.S. facilities are located in Wilmington, North Carolina; Research Triangle Park, North Carolina; Natick, Massachusetts; Charleston, South Carolina; and Shawnee, Kansas. These facilities provide approximately 358,000 square feet of total operational and administrative space. Our primary European facility is located in Neu-Ulm, Germany and includes approximately 112,400 square feet of operational and administrative space. We also have U.S. sales representatives for our Development Services business based throughout the United States and foreign sales representatives for such business based in Japan, Sweden, Germany, and the U.K. We believe that our facilities are adequate for our current operations and that suitable additional space will be available when needed.

22

Primary Operating Facilities

We have been notified by the landlords of our leased facilities in New Jersey and California, as well as one leased facility in North Carolina, that we are in default for failure to make the April 2005 lease payments for these facilities. We are not using any of these leased facilities.

Item 3. Legal Proceedings

We are party to lawsuits and administrative proceedings incidental to the normal course of our business. Our material legal proceedings are described below. We cannot predict the outcomes of these matters. As noted below, we believe that any liabilities related to such lawsuits or proceedings, if adversely determined, could have a material adverse effect on our consolidated financial condition, results of operations and cash flows. Prosecuting and defending these material legal proceedings, including responding to governmental inquiries, has resulted, and is

23

expected to continue to result, in a significant diversion of management’s attention and resources and an increase in professional fees.

Government Investigations

In April 2004, in connection with an investigation conducted by the United States Attorney’s Office for the Western District of North Carolina (the “U.S. Attorney’s Office”), we received five federal grand jury subpoenas for document production and potential testimony related to, among other things, certain transactions regarding our 2002 and 2003 financial information, the terms, conditions of employment, and compensation arrangements of certain of our senior management personnel, compensation and incentive arrangements for employees responsible for the sale of our Brethine, Darvocet, calcitriol, azathioprine and Darvon Compound products, quantities of the foregoing products in distribution channels, financial benefits with respect to specified corporate transactions to our senior management and others, certain loans obtained by us, extensions of credit, if any, by us to officers or directors, accounting for sales and returns of our foregoing products, our analysts’ conference calls on financial results, internal and external investigations of pharmaceutical product sales activities, and related matters. The SEC has also commenced an investigation and we have received a subpoena from the SEC covering similar matters. In addition, both the U.S. Attorney’s Office and the SEC have made informal requests for documents and other information related to these matters. Certain of our current and former officers, directors, and employees have received subpoenas to appear before the federal grand jury or requests to provide information to the U.S. Attorney’s Office. A former officer of our company, David M. Hurley, has been advised by the U.S. Attorney’s Office that he is a target of its investigation.

We and a special committee of our Board of Directors established in February 2004 (the “Special Committee”) have agreed to cooperate fully with the government investigations, and the Special Committee has shared information regarding its investigation with the SEC and the U.S. Attorney’s Office.

The U.S. Attorney’s Office, SEC, and other government agencies that are investigating or might commence an investigation of our company could impose, based on a claim of fraud, material misstatements, violation of false claims law, or otherwise, civil and/or criminal sanctions, including fines, penalties, and/or administrative remedies. If any government sanctions are imposed, which we cannot predict or reasonably estimate at this time, our business and financial condition, results of operations, or cash flows could be materially adversely affected. These matters have resulted, and are expected to continue to result, in a significant diversion of management’s attention and resources and in significant professional fees. We have agreed to advance expenses reasonably incurred by certain of our current directors and current and former officers in connection with these investigations. This advancement of expenses was conditioned upon the execution by such persons of undertakings to assist and cooperate with us in connection with the investigations and to repay to us any advanced funds in the event that (i) we determine that certain representations made by such directors and officers are inaccurate, (ii) we are prohibited from providing indemnification to such directors or officers pursuant to Delaware law or our organizational documents, or (iii) such directors or officers stop cooperating with us on the investigations. For a description of the amount of expenses advanced in 2004 and the first

24

part of 2005 to our current executive officers and directors, see Part III, Item 13, “Certain Relationships and Related Transactions.”

On January 2, 2004, we received separate letters from the Kentucky Office of Attorney General and the Florida Office of Attorney General advising that each was currently investigating allegations regarding our pricing practices related to our average manufacturer price and best price calculations that are used by the government to set Medicaid reimbursement rates. Neither letter requested that we provide any information, and each letter merely requested that we retain all documents with respect to these calculations pursuant to a newly adopted federal regulation that would have permitted the destruction of these documents three years after the applicable prices were reported, except to the extent we were aware of an ongoing investigation. It is our understanding that many other pharmaceutical companies received similar letters at that time from attorneys general in a number of states and that such letters may have been in response to the new federal regulation that would have otherwise allowed the destruction of documents reflecting these pricing calculations. A number of attorneys general, including the Florida and Kentucky attorneys general, petitioned the U.S. Secretary of Health and Human Services to withdraw the new regulation. We are not aware of any further developments in these investigations.

Federal Securities, Derivative and ERISA Litigation

We, certain of our current and former officers and directors, and our independent registered public accountants have been named as defendants in purported stockholder class action lawsuits alleging violations of federal securities laws. The securities lawsuits were filed beginning in February 2004 and are pending in the U.S. District Court for the Eastern District of North Carolina. By order dated April 16, 2004, the district court consolidated the securities lawsuits into one consolidated action, and on February 11, 2005, the plaintiffs filed a consolidated amended complaint. The amended securities complaint asserts claims arising under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder on behalf of a class of purchasers of our common stock during the period from April 24, 2002 through and including June 15, 2004. The securities complaints allege generally that the defendants knowingly or recklessly made false or misleading statements during the Class Period concerning our financial condition and that our financial statements did not present our true financial condition and were not prepared in accordance with generally accepted accounting principles. The amended securities complaint seeks certification as a class action, unspecified compensatory damages, attorneys’ fees and costs, and other relief.

A stockholder derivative suit was filed in the United States District Court for the Eastern District of North Carolina on August 26, 2004 by two putative shareholders against current and former members of the Company’s Board of Directors and senior management. Our company is named as a “nominal defendant.” The complaint alleges that the individual director and officer defendants breached fiduciary and contractual obligations to our company by implementing an inadequate system of internal control over financial reporting and causing our company to issue false and misleading statements exposing our company to securities fraud liability, and that certain defendants engaged in insider trading. The complaint seeks unspecified compensatory damages, attorneys’ fees and costs, and other relief.

25

In addition, we and certain of our current and former directors, officers and employees have been named in a purported class action brought by an aaiPharma pension plan participant and beneficiary asserting claims under ERISA on behalf of a class of all persons who are or were participants in or beneficiaries of the aaiPharma Inc. Retirement and Savings Plan during the period from April 24, 2002 to June 15, 2004. An amended complaint was filed on March 14, 2005 which alleges generally that the defendants breached fiduciary duties owed under ERISA with respect to the prudence and lack of diversification of investment of Plan assets in our common stock, by misleading participants and beneficiaries of the Plan regarding our earnings, prospects and business condition, by failing to act in the sole interest of Plan participants, and by failing to monitor the actions of other Plan fiduciaries. The complaint seeks certification as a class action, unspecified compensatory damages, attorneys’ fees and costs, and other equitable relief. This ERISA lawsuit is pending in U.S. District Court for the Eastern District of North Carolina. The proceedings in this matter will be coordinated with the securities lawsuits described above.

These lawsuits are at an early stage. Our response to the amended securities complaint is not due until May 26, 2005, and our response to the amended ERISA complaint is not due until June 30, 2005 at the earliest. By agreement, no response to the derivative suit is due until 60 days after the plaintiffs file their amended complaint, and no discovery has yet occurred in either the securities or derivative litigation. Only limited discovery has occurred in the ERISA litigation.

By, and subject to, the terms of our bylaws, we have certain obligations to indemnify our current and former officers, directors and employees who have been named as defendants in these lawsuits. We have purchased directors and officers liability insurance (“D&O insurance”) that may provide coverage for some or all of these lawsuits and governmental investigations. We have given notice to our D&O insurance carriers of the securities and derivative suits described above, and the insurers have responded by requesting additional information and by reserving their rights under the policies, including the rights to deny coverage under various policy exclusions or to rescind the policies. There is a risk, however, that the D&O insurance carriers will rescind the policies or that some or all of the claims or expenses will not be covered by such policies; or that, even if covered, our ultimate liability will exceed the available insurance. Our fiduciary liability insurance carrier has denied coverage of claims made in connection with the original ERISA litigation complaint; the amended ERISA complaint is under review by us for potential fiduciary policy coverage. Although we intend to vigorously pursue all defenses available in these lawsuits, an adverse determination in these lawsuits or an inability to obtain payment under our insurance policies for litigation and indemnification costs and any damages ultimately borne by us as a result of these lawsuits and investigations could have a material adverse effect on our business, financial condition, results of operations or cash flows.

Patent Litigation

We are a party to a number of legal actions with generic drug companies. We are involved in two lawsuits centered on our omeprazole-related patents, including one lawsuit brought by us against an alleged infringer of our patents and another lawsuit which was brought by a third party against us and is currently essentially inactive. Both lawsuits are described in more detail below. Omeprazole is the active ingredient found in Prilosec, a drug sold by AstraZeneca PLC. An

26

additional lawsuit brought against us by Andrx Pharmaceuticals, Inc. involving omeprazole was dismissed without prejudice in December 2004.

An omeprazole-related case has been filed against us by Dr. Reddy’s Laboratories Ltd. and Reddy-Cheminor Inc. in the U.S. District Court for the Southern District of New York in November 2001. The plaintiffs in this case have challenged the validity of five patents that we have obtained relating to omeprazole and are seeking a declaratory judgment that their generic form of Prilosec does not infringe these patents. Additionally, they have alleged misappropriation of trade secrets, tortious interference, unfair competition and violations of the North Carolina Unfair Trade Practice Act. We have denied the substantive allegations made in these cases. A second lawsuit brought by the plaintiffs involving omeprazole was filed in July 2001 and was dismissed without prejudice in March 2005.

The case is in the early stages of litigation. However, while these plaintiffs have sought approval from the FDA to market a generic form of Prilosec, to the best of our knowledge as of April 18, 2005, no such FDA approval has been granted to them. In addition, these plaintiffs’ omeprazole product has been found in separate litigation to infringe certain patents of AstraZeneca and the infringement findings have been upheld on appeal. The lawsuit is essentially inactive at this time. Only limited discovery has occurred in this lawsuit and no additional discovery is currently being sought. No date has been set for the trial. In the event that the lawsuit again becomes active, we intend to vigorously defend the patents’ validity and to determine whether or not the plaintiffs’ product infringes any of our relevant patents.

The other lawsuit involving our omeprazole patents was brought in December 2002 by us against Kremers Urban Development Co., Schwarz Pharma Inc. and Schwarz Pharma AG (collectively, together with the other named defendants, “KUDCO”) in the U.S. District Court for the Southern District of New York. KUDCO has a generic omeprazole product with final FDA marketing approval, was found not to infringe the AstraZeneca patents in the separate AstraZeneca patent litigation, and is currently selling its generic substitute for Prilosec in the U.S. marketplace.

We initially brought the lawsuit alleging infringement of our U.S. Patent No. 6,268,385. Following the collection of additional information concerning KUDCO’s commercially marketed product, we sought leave of the court to file an amended complaint, adding additional claims of infringement and contributory infringement under our U.S. Patent No. 6,326,384 and joining as defendants Schwarz Pharma Manufacturing Inc. and Schwarz Pharma USA Holdings Inc. These two patents include, among other claims, claims directed to compositions and methods wherein certain characteristics of solid state omeprazole are essentially the same in formulated drug product as in its active ingredient.

In September 2003, the judge granted us leave to file the first amended complaint adding our second patent and the additional KUDCO affiliates to the lawsuit. Following initial discovery, we sought leave of the court to file a second amended complaint, adding Kremers Urban Inc., another KUDCO affiliate, to the lawsuit. On February 26, 2004, the judge granted us leave to file the second amended complaint, adding Kremers Urban Inc. to the lawsuit.

KUDCO has filed its answer to our complaint, denying our claims, asserting various affirmative defenses to our claims (including patent invalidity and product non-infringement), and asserting

27

counterclaims and antitrust violations under federal and state antitrust laws. KUDCO is also contesting the personal jurisdiction of the court over all of the defendants in this lawsuit other than Kremers Urban Development Co., Kremers Urban Inc. and Schwarz Pharma Inc. Motions on the jurisdictional issues are pending before the court. We have denied the substantive allegations made by KUDCO in its counterclaims, and the court has granted our motion to stay antitrust discovery.

Substantial discovery of both sides’ documents and of defendants’ product samples has occurred in the lawsuit, although both sides asserted numerous discovery deficiencies against the other. On February 26, 2004, the judge assigned the discovery disputes to a federal magistrate for resolution. Discovery is continuing at this time. No trial date has been set.

We have previously indicated to KUDCO a willingness to grant a license under our omeprazole patents for an appropriate royalty. In the absence of KUDCO taking a royalty-bearing license, we are seeking damages equal to a reasonable royalty on all infringing sales by the KUDCO defendants since commercial launch of their generic substitute for Prilosec on December 9, 2002 through the date of a judicial decision in the litigation, and a permanent injunction on subsequent sales thereafter (unless KUDCO takes a license), among other remedies, in the event that we ultimately prevail in the litigation. The KUDCO defendants have publicly confirmed sales of their generic omeprazole product during the first twenty-two months after launch of their product of approximately $1.3 billion. In the absence of a license or settlement, we intend to vigorously prosecute the case, defend our patent rights and defend against the foregoing defenses and counterclaims asserted by KUDCO. It is possible that the omeprazole-related patents subject to the foregoing four lawsuits will be found invalid, unenforceable or not infringed and, while currently stayed by the court, it is possible that the defendants’ antitrust counterclaims in the KUDCO litigation will ultimately be allowed to proceed and be litigated. If adverse findings were to occur, they could have a material adverse effect on our consolidated financial statements, results of operations and cash flow.

In cases where we have initiated an action, we intend to prosecute our claims to the full extent of our rights under the law. In cases where we are named defendants, we intend to vigorously pursue all defenses available.

Athlon Litigation

On April 15, 2004, we filed a lawsuit against Athlon Pharmaceuticals, Inc. in the U.S. District Court for the Northern District of Georgia seeking a declaratory judgment that we were entitled to terminate the Service Agreement (the “Athlon Service Agreement”) dated July 16, 2003, as amended, between us and Athlon as well as damages and injunctive relief for material breaches of the Athlon Service Agreement by Athlon. The Athlon Service Agreement incorporated the terms and conditions pursuant to which representatives of Athlon would promote the sale of our Darvocet A500 product to physicians. We initially paid Athlon $3,350,000 to build its sales force to promote the sale of our Darvocet A500, and the terms of the Athlon Service Agreement would require us to pay Athlon an additional $1,200,000 each month for such services for the contract period of 36 months, commencing in October 2003, subject to Athlon’s compliance with certain representations, warranties and covenants, some of which are described below.

28

The lawsuit asserts that Athlon has materially breached the Athlon Service Agreement in several ways, including failure to: (i) provide the required number of sales representatives during our launch of Darvocet A500 commencing in October 2003, (ii) use its best efforts to promote Darvocet A500 at the targeted levels of first and second pharmaceutical details to physicians, (iii) perform the services to the best of its ability, as contractually required, and (iv) require its sales representatives to perform the contracted services, as required, in a professional manner consistent with industry standards and in conformance with that level of care and skill ordinarily exercised by professional contract sales organizations in similar circumstances. The lawsuit also asserts that Athlon breached its representation and warranty that it would perform, and would require its sales representatives to perform, the contracted services in substantially the same manner that it would promote Athlon’s own products.

Athlon has asserted several counterclaims, including breach of an implied covenant of good faith in fair dealing and anticipatory breach of the contract. We have filed a reply denying these allegations.

In May 2004, we ceased making payments under the Athlon Service Agreement, and on June 4, 2004, we sent a notice of termination of the agreement to Athlon. On July 7, 2004, we amended the lawsuit to assert claims of fraud and breaches of contract and implied covenants, seeking to recover compensatory and punitive damages and attorneys’ fees. Athlon has amended its counterclaim to assert fraud claims and to seek punitive damages.

On August 11, 2004, Athlon filed a lawsuit against us, also in the U.S. District Court for the Northern District of Georgia, alleging that we breached the Asset Purchase Agreement (the “Purchase Agreement”) dated July 16, 2003 pursuant to which we acquired Darvocet A500 from Athlon. Athlon is seeking royalties it alleges we failed properly to calculate and pay under the Purchase Agreement, as well as attorneys’ fees. We have denied the substantive allegations in this case and filed counterclaims seeking to recover an overpayment in the royalties owed to Athlon.

The two cases have been consolidated and are currently in discovery. No trial date has been set. We intend to prosecute our claims and counterclaims, and defend against the claims and counterclaims made by Athlon, in these lawsuits to the fullest extent permitted by law.

CIMA Litigation

CIMA Labs, Inc. commenced an action against us in the Fourth Judicial District, State of Minnesota, Hennepin County, on August 11, 2004. In its complaint, CIMA alleges that we are liable for fraudulent inducement, negligent fraudulent misrepresentation, fraudulent concealment, breach of contract, and attorneys fees and interest, all arising out of an Agreement and Plan of Merger dated as of August 5, 2003, between CIMA and aaiPharma (the “Merger Agreement”). CIMA alleges that in the negotiations leading up to the Merger Agreement, we engaged in misrepresentations and concealments relating to our financial condition, and that in the Merger Agreement, we made false representations and warranties concerning our financial statements, regulatory filings, and absence of material adverse effects, among other things. Much of CIMA’s claims are based on disclosures made by us in our Amended Form 10-Q, which we filed with the SEC on June 24, 2004, for the period ended June 30, 2003. CIMA seeks

29

to recover the amount of $11.5 million, which it paid to us as a termination fee under the Merger Agreement, plus additional sums it spent for professional fees and due diligence activities (which it claims are in excess of $5 million), attorneys’ fees, litigation expenses, and interest. We answered CIMA’s complaint on September 17, 2004, denying all liability and raising a number of affirmative defenses. Among other things, we assert that CIMA’s termination of the Merger Agreement barred any claims except those based on our willful breach of its representations, warranties, covenants, or other agreements as set forth in that Agreement. In addition, we affirmatively allege that CIMA terminated the Merger Agreement and paid the termination fee not as the result of any alleged breach by us, but rather as part of CIMA’s plan to secure and act on a “Superior Proposal” from another bidder, which allowed it to consummate a transaction with that other bidder on terms that it believed were more favorable to it than those set forth in the Merger Agreement. The case is scheduled for trial in the fall of 2005, and the parties are currently involved in document productions and written discovery. On January 14, 2005, the Minnesota court rejected a relevance objection made by us in response to CIMA’s discovery requests and ordered us to produce voluminous documents to CIMA. On March 21, 2005, the Minnesota court approved a motion to compel made by CIMA against us to produce documents by April 5, 2005 and an extensive privilege log by April 20, 2005 with respect to documents generated by our legal counsel in the internal investigation. We have produced the documents and have moved to delay the production of the privilege log. The Court may deny our motion for additional time to produce the privilege log and may sanction us, including holding us in contempt or entering a default judgment against us. We intend to contest the action as vigorously as our limited resources permit.

Leased Properties and Assets

We have discontinued operations at our New Jersey facility, which constitutes approximately 75,000 square feet of laboratory and office space, but continue to be obligated under the lease for this facility, which expires in 2010. On April 5, 2005, we received a written notice from the landlord for this facility indicating that we are in default under the lease for this facility due to our failure to timely pay rent, and that the landlord has filed a landlord/tenant eviction action against us. We have not been served with formal notice of this proceeding or a formal complaint. We also have stopped paying rent for certain other leased properties that we no longer use, and have received notices of default from the landlords of these properties due to our failure to make the required rent payments. In addition, we have been advised that we are in default of the lease documents related to an airplane that we no longer use and that the lessor has terminated our rights under these lease documents.

Item 4. Submission of Matters to a Vote of Security Holders

On December 15, 2004, we held our 2004 annual meeting of stockholders. The total number of shares outstanding as of the record date, October 29, 2004, was 28,585,582. The matters voted on at the meeting and the results are as follows:

30

     Election of Directors:

Proposal to amend the 1997 Stock Option Plan by authorizing the issuance of an additional 1,500,000 shares of our common stock under the Plan:

Proposal to ratify the appointment of Ernst & Young as independent auditors of the Company for the fiscal year ended December 31, 2004:

No other matters were voted on at the meeting.

31

Executive Officers

The following table contains information concerning our executive officers as of April 1, 2005:

Ludo Reynders, Ph.D. joined the Company in September 2004 as the Chief Executive Officer and President. Prior to joining the Company, Dr. Reynders served from 2003 to September 2004 as managing member of Bronzewood LLC, a private company focused on improving productivity in drug development. Dr. Reynders was managing director of the PharmaBio group of Quintiles Transnational Corporation from 2002 to 2003. Dr. Reynders also held the position of Chief Executive Officer of Quintiles’ Clinical Development Services and Product Development Services groups from 2000 to 2002 and 1996 to 2000, respectively. He began his career with Quintiles in 1988.

Timothy R. Wright joined the Company in April 2004 as President of the Pharmaceuticals Division and was appointed a director in May 2004. Prior to joining the Company, Mr. Wright served as the President, Global Commercial Operations for Elan Bio-pharmaceuticals from February 2001 to December 2003. Before that, Mr. Wright served as a Senior Vice President of Healthcare Product Services with Cardinal Health, Inc. from May 1999 to January 2001. Mr. Wright also held senior management positions with DuPont Merck Pharmaceutical Company from 1984 to 1999.

Michael W. George joined the Company as Chief Administrative Officer, a position he relinquished in March 2005, and as Executive Vice President in July 2004. Prior to joining aaiPharma, Mr. George was President and Chief Executive Officer of Michael George and Associates, a pharmaceutical-oriented consulting firm, from April 2002 to July 2004. Mr. George was also President, North America for Elan Pharmaceuticals from November 2001 to April 2002 and President and Chief Executive Officer of UROCOR INC., a company that specializes in oncology products and services, from August 1998 to November 2001.

Matthew E. Czajkowski joined the Company in December 2004 having previously worked with POZEN Inc., where he served as Senior Vice President Finance and Administration and Chief Financial Officer from 2000 to 2004. Prior to his service with POZEN, he was a private consultant from 1998 to 2000 and Managing Director of Societe Generale from 1997 to 1998.

32

Additionally, Mr. Czajkowski has held senior management positions with Goldman, Sachs & Co. and Wheat First Butcher Singer, Inc.

William H. Underwood is a director and Executive Vice President — Corporate Development of aaiPharma. He has served as a director since 1996, as Chief Operating Officer from 1995 to 1997, as Executive Vice President since 1992, and as Vice President from 1986 to 1992. Mr. Underwood held various positions in the pharmaceutical and cosmetic industries prior to joining aaiPharma in 1986, including Director of Quality Assurance and Director of Manufacturing at Mary Kay Cosmetics, Inc. and Group Leader of Bacteriological Quality Control at Burroughs-Wellcome Co.

Gregory F. Rayburn joined the Company as interim Chief Operating Officer in March 2004. Mr. Rayburn is also a senior managing director and the Interim Management practice leader with FTI Palladium Partners, the interim management practice of FTI Consulting, Inc. (“FTI”), a leading provider of turnaround, performance improvement, financial and operational restructuring services. Mr. Rayburn provides services to us through a contract between the Company and FTI Palladium Partners. Mr. Rayburn joined FTI Palladium Partners in 2003. Prior to FTI Palladium Partners, Mr. Rayburn served a principal with AlixPartners from 2000 to 2003. While at AlixPartners, Mr. Rayburn served as the Chief Restructuring Officer of WorldCom. Before that, Mr. Rayburn served from 1998 to 2000 as the president of The Capstone Group LLC, a private investment partnership. Prior to serving as president of Capstone, Mr. Rayburn was a partner in the Corporate Recovery Services Group of Arthur Andersen LLP.

Gregory S. Bentley has served as Executive Vice President and General Counsel of aaiPharma since June 1999. Mr. Bentley served as Secretary of aaiPharma from June 1999 to April 2002. Prior to joining aaiPharma, Mr. Bentley served from 1994 to 1999 as Vice President, Regulatory and Quality for Siemens Medical Systems, Inc., a leading medical device company and a subsidiary of Siemens Corporation. Prior to joining Siemens Corporation as Associate General Counsel in 1986, Mr. Bentley practiced law with the law firm of Shearman & Sterling in New York.

John Harrington joined the Company in July 2004 as Executive Vice President of Human Resources. Mr. Harrington served as Senior Vice President of Human Resources for Quintiles Transnational Corporation from January 2000 through March 2004 and head of Worldwide Human Resources for Quintiles from 1997 through December 1999. Mr. Harrington was previously European Director of HR for Syntex, a Palo Alto based pharmaceutical company subsequently acquired by Quintiles. Prior to joining the pharmaceutical industry, Mr. Harrington held a number of increasingly senior HR posts with British Petroleum over a 20-year period.

33

PART II

Item 5. Market for the Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

Prior to April 18, 2005, our common stock was traded on the NASDAQ National Market System under the symbol “AAII.” Our common stock was delisted from the NASDAQ National Market System at the open of trading on April 18, 2005, and began trading on the Pink Sheets under the symbol “AAII.PK” on that day. The price range of our common stock is listed below by quarter for the years ended December 31, 2004 and 2003:

The price ranges for the first quarter of 2003 have been adjusted for the three-for-two common stock split, affected through a stock dividend, paid on March 10, 2003.

We estimate there were approximately 5,180 holders of record for our common stock as of October 2004. No cash dividends were declared during 2004 or 2003, and our senior secured credit facilities prohibit us from paying cash dividends.

The background of the delisting of our common stock is as follows: in 2004, we did not timely file our Annual Report on Form 10-K for the year ended December 31, 2003 and our Quarterly Report on Form 10-Q for the period ended March 31, 2004. We received notices from the NASDAQ Stock Market (“NASDAQ”) that, due to the delay in filing these reports, we were not in compliance with certain NASDAQ marketplace rules and that our common stock would be subject to delisting. We requested and participated in a hearing before a NASDAQ listing qualifications panel on April 29, 2004. On June 21, 2004, NASDAQ notified us that the listing qualifications panel had determined to continue the listing of our common stock if we met certain conditions, including the prospective condition that we file with the SEC and NASDAQ all periodic reports for reporting periods ending on or before June 30, 2005 on or before the deadline for the filing of those periodic reports. In its notification, NASDAQ advised that the filing of a Notification of Late Filing on Form 12b-25 would not automatically extend the deadline for the filing of a periodic report for the purpose of this condition, and further that a failure to satisfy this condition could result in the delisting of our common stock without the right to a hearing.

On March 16, 2005, we provided notice to NASDAQ and the listing qualifications panel of our failure to satisfy this condition, as a result of the failure to file this Annual Report on Form 10-K for the fiscal year ended December 31, 2004 by March 16, 2005, and requested that the listing

34

qualifications panel permit the continued listing of our common stock on NASDAQ if we filed this Form 10-K by April 30, 2005. As a result, the listing qualifications panel held a hearing with us on April 7, 2005. At the hearing, we again requested that NASDAQ continue the listing of our common stock on the condition that we file this Form 10-K by April 30, 2005. On April 14, 2005, we received notice from NASDAQ that our common stock would be delisted from NASDAQ effective with the open of business on Monday, April 18, 2005 as a result of our failure to timely file this Form 10-K as required by NASDAQ Marketplace Rule 4310(c)(14) and by the continued listing condition discussed above. NASDAQ’s April 14, 2005 notice stated that the listing qualifications panel had rejected our request. Our common stock was delisted from NASDAQ at the open of business on Monday, April 18, 2005 and now trades on the Pink Sheets under the symbol “AAII.PK.”

PURCHASES OF EQUITY SECURITIES

We made the following purchases of our common stock during the fourth quarter of 2004:

In conjunction with the hiring of three executive officers in 2004, we granted such executive officers a total of 104,817 shares of restricted stock. The shares become vested if the executives are employed by us on the anniversary dates, either six months or one year, from their respective hire date.

35

Item 6. Selected Consolidated Financial Data.

The selected historical financial data set forth below are not necessarily indicative of the results of future operations and should be read in conjunction with “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and our consolidated financial statements and related notes and other financial information appearing elsewhere in this report.

SELECTED FINANCIAL DATA

36

37

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations

You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and related notes included elsewhere in this report. The notes to our consolidated financial statements set forth our critical accounting policies, including policies relating to revenue recognition, intangible assets, inventories and income taxes. These policies are summarized below under “Critical Accounting Policies.”

On January 30, 2003, our Board of Directors approved a three-for-two stock split of our common shares. On March 10, 2003, each stockholder received one additional share of common stock for every two shares such stockholder owned on the record date of February 19, 2003. All share and per share amounts have been restated to reflect the stock split for each period presented as if it had occurred at the beginning of the period.

In the fourth quarter of 2004, we began reporting revenues and expenses under the guidelines of the Emerging Issues Task Force Issue No. (“EITF”) 01-14, “Income Statement Characterization of Reimbursements Received for ‘Out-of-Pocket’ Expenses Incurred.” EITF 01-14 requires that reimbursements received for out-of-pocket expenses be characterized as revenue. All prior period amounts have been reclassified to comply with this release. The adoption of this rule resulted only in the gross up of revenues and expenses and had no impact on earnings.

Overview of Results of Operations

Our financial results significantly deteriorated in 2004. Our net revenues declined to $215.3 million in 2004, compared to net revenues of $236.9 million in 2003. We incurred a net loss of $191.2 million in 2004, compared to a net loss of $32.7 million in 2003.

Our net revenues for 2004 decreased from 2003 as a result of a significant reduction in pharmaceutical product sales. The reduction resulted from decreased sales volumes in our Darvon/Darvocet and Brethine product lines, which were affected by the amount of inventory previously sold into the wholesale channel, as well as the divestiture of our M.V.I. and Aquasol product lines in the second quarter of 2004, as partially offset by contributions from our Roxicodone and Oramorph product lines, which we acquired in December 2003.

The wholesalers that we deal with have recently limited, and may continue to limit, their purchases of pharmaceutical products from us. We believe these wholesalers have reduced their purchases in order to minimize any exposure that could result from our liquidity position. In addition, we are seeing an emerging trend of weakness in our development services business that we believe is a result of customers being less willing to engage us for long-term development services projects due to our liquidity issues. This weakness in our long-term development services business has been partially offset by continued strength in short-term analytical development services projects.

In addition to a decline in net revenues, the primary factors that contributed to our substantial net loss in 2004 include:

38

	•	Impairment charges that we recorded in 2004 due to the impairment of the intangible assets associated with our Darvon/Darvocet ($87.1 million) and Brethine ($6.4 million) products.
	•	$11.0 million in professional fees that we incurred in connection with the Special Committee’s investigation described below under “ — Special Committee Investigation”;
	•	$22.4 million in charges recorded in connection with work force reductions and facility closures resulting from the implementation of several restructuring plans in 2004; and
	•	An $11.7 million charge, and corresponding reserve, related to a pharmaceutical product manufacturing supply agreement entered into in 2003 requiring us, subject to the terms and conditions of the agreement, to purchase a minimum level of certain products on a take-or-pay basis by September 2006.

As a result of our substantial and recurring operating losses, we believe that we will not have adequate sources of liquidity to fund our operations in the near term unless we obtain additional sources of liquidity. In March 2005, we received a tax refund of approximately $11.3 million, all or substantially all of which was required to be paid down under our senior credit facilities. Events of default had also occurred under our senior credit facilities that would prohibit borrowings thereunder absent a waiver from our senior lenders. On March 31, 2005, we entered into a waiver agreement pursuant to which our senior lenders agreed to forbear in exercising remedies with respect to these existing events of default until the earlier of April 30, 2005 or the occurrence of another default under the waiver agreement or our senior credit facilities. Upon any such forbearance termination, our senior lenders could accelerate the debt then outstanding under our senior credit facilities unless all events of default have been cured. This waiver agreement also permitted us to immediately use approximately $5.7 million of the tax refund to meet budgeted liquidity needs and required us to temporarily paydown revolving loans under the senior credit facilities with the remaining $5.6 million of the tax refund. Despite the existing events of default, the waiver permitted us to reborrow this $5.6 million, in weekly draws, to meet budgeted liquidity needs. We have fully borrowed this $5.6 million, and no other borrowings are permitted under our senior credit facilities absent a consent from our senior lenders.

In light of our current financial condition, we believe that our operations can no longer support our existing debt and that we must restructure our debt to levels that are more in line with our operations. Thus, it is highly likely that we will seek relief under chapter 11 of the U.S. Bankruptcy Code which would substantially dilute and may eliminate the interests of the holders of our common stock. For additional discussion of our financial condition and liquidity, see “ — Liquidity and Capital Resources.”

Business Overview

Management and Operational Changes

Since January 1, 2004, we have experienced substantial management changes. In February 2004, David Hurley, our Chief Operating Officer and President of our Pharmaceuticals Division resigned. In March 2004, Dr. Philip Tabbiner was replaced as our Chief Executive Officer by

39

Dr. Frederick D. Sancilio, and Gregory F. Rayburn, a senior managing director with FTI Palladium Partners, was named to the position of interim Chief Operating Officer. In April 2004, Timothy R. Wright was hired as the President of our Pharmaceuticals Division. In May 2004, William L. Ginna stepped down from his position as Executive Vice President and Chief Financial Officer and Gina Gutzeit, a senior managing director with FTI Palladium Partners, was named as interim Chief Financial Officer. In July 2004, we hired Michael W. George as our Chief Administrative Officer, a position he relinquished in March 2005, and as an Executive Vice President, and John Harrington joined the Company as Executive Vice President of Human Resources. In September 2004, Dr. Frederick D. Sancilio stepped down from his positions as our President, Chief Executive Officer and Chief Scientific Officer and Dr. Ludo Reynders was appointed President and Chief Executive Officer. Also in September, 2004, Dr. Vijay Aggarwal resigned as President, AAI Development Services, and was replaced by Michael George as Executive Vice President in charge of AAI Development Services. Due to Dr. Reynders hospitalization for suspected pneumonia from November 9, 2004 through November 22, 2004, Timothy R. Wright was appointed interim President and Chief Executive Officer during such period. In December 2004, Matthew E. Czajkowski joined our company as Executive Vice President and Chief Financial Officer, replacing Gina Gutzeit. In addition to serving as Executive Vice President and Chief Financial Officer, Mr. Czajkowski was appointed Chief Administrative Officer in March 2005. In March 2005, Michael George joined the Pharmaceuticals Division and Dr. Reynders took direct operational control over AAI Development Services.

In 2004, we operated three business units — a pharmaceutical product sales business operated through our Pharmaceuticals Division, a development services business operated through our AAI Development Services Division and a product development business operated through our Research and Development Division. In March 2005, we reorganized our operating structure to reflect our decision to curtail our research and development activities in light of our financial condition. At that time, our Research and Development Division was no longer actively engaged in any shared-risk development projects. Personnel involved in the development of proprietary products were assigned to our Pharmaceuticals Division, while personnel that had focused on independent research or shared-risk development projects were assigned to fee-for-service development projects in our AAI Development Services Division. As a result of this reorganization of our operating structure, we currently operate in only two business segments — proprietary pharmaceutical product development and sales through our Pharmaceuticals Division and development services offered to third parties through our AAI Development Services Division.

Pharmaceuticals Division — Our Product Sales Business

Our product sales business unit commercializes pharmaceutical products. We currently market products under our various brand names as well as certain generic products. The principal costs of this business in 2004 included manufacturing costs, either internally or under agreements with third party manufacturers, selling expense of our sales force (which we terminated in the fourth quarter of 2004), payments in connection with a contract sales force (which we ceased paying in May 2004 in connection with the termination of the Athlon Services Agreement) and general and administrative costs of our business unit management team. During 2004, net revenues from product sales were $77.8 million, or 36% of our consolidated net revenues.

40

Our results of operations can be influenced by the timing of purchases made by our customers and the magnitude of the inventories of our products that our customers desire to maintain. These customers are wholesalers and may increase their purchases if they anticipate a price increase. Wholesalers may anticipate a price increase due to the timing of prior increases, the acquisition of a product by a new supplier or other reasons. Any increase in revenues during one period due to an anticipated price increase may likely be offset by decreased revenues in subsequent periods. Thus, as described in more detail below, there may be some volatility of our pharmaceutical product revenues in future periods due to the timing of our customers’ purchasing decisions.

We believe that there is a significant shift occurring in the business model of wholesale distributors of pharmaceutical products. Historically, wholesalers have made a significant portion of their revenue by negotiating discounts on purchases and by purchasing product prior to anticipated price increases in order to sell product at the new, higher price. Wholesalers are now demanding that sellers of pharmaceutical products execute distribution services agreements that require the payment of a service fee related to the purchase and distribution of product. These fees may vary according to the size of the purchase and according to whether the products are branded or generic. Except for our exclusive distribution agreement with a subsidiary of Cardinal Health for our Brethine product, we have not entered into distribution services agreements with our wholesaler customers. However, we anticipate that we may be required to do so in the near future.

We have been exploring a potential sale of some or all of the assets of our Pharmaceuticals Division, as well as other operating assets. On March 31, 2005, we entered into a limited exclusivity agreement with a potential purchaser of certain of the assets of our Pharmaceuticals Division to facilitate continued due diligence and negotiation over a potential sale. This written exclusivity agreement expired by its terms on April 22, 2005, though we are continuing to negotiate with this potential purchaser on an exclusive basis. We have not reached a definitive agreement with this potential purchaser regarding a sale and we cannot provide any assurance that any material asset sale will be agreed upon or completed. In addition, we have not determined to sell any material assets, and we plan to continue to operate our Pharmaceuticals Division if we do not complete such a sale of its assets.

AAI Development Services — Our Development Services Business

Our development services business unit, AAI Development Services, provides a comprehensive range of development services through two primary groups, a nonclinical group and a clinical group. The nonclinical group develops and validates methods, analyzes and tests various chemical compounds, and provides small scale manufacturing of chemical compounds to be used for human clinical trials as well as for commercial distribution. The services performed by the nonclinical group also include chemical analysis, chemical synthesis, drug formulation, bioanalytical testing, product life cycle management services, and regulatory and compliance consulting. All of these nonclinical services involve either laboratory work, small scale manufacturing or consulting services. The clinical group performs testing for customers of new pharmaceutical products in humans under controlled conditions as part of the regulatory approval process for pharmaceutical products. These clinical services involve conducting human clinical studies, and the statistical analysis relating to these studies.

41

Both the nonclinical and clinical groups receive requests for services from customers, often on a competitive basis. These projects vary in length from one month to several years. In general, our customers may cancel a project upon 30 days’ notice. The principal expenses of this business are labor costs, including employee benefits, and equipment and facility-related costs. During 2004, net revenues of our development services business unit were $94.9 million, or 44% of our consolidated net revenues.

Research and Development

In 2004 and early 2005, our product development business unit used our research and development expertise and capabilities to enhance and develop new drug delivery technologies and improve existing pharmaceutical products. In March 2005, we reorganized our research and development activities. Our Pharmaceuticals Division is now tasked with the oversight of our development efforts on our product pipeline, while our AAI Development Services Division now manages our intellectual property portfolio of patents and drug delivery technologies.

We apply our drug development expertise to internally develop our own new products, develop our customers’ products and improve our acquired products. We license the developed technologies and products to customers, in some cases before the development is complete. With respect to our customers’ products, we generally receive payments for our efforts and innovations upon the occurrence of defined events, known as milestones, which are intended to help cover the costs of development. These milestone payments are not refundable. We also may receive royalties on the eventual sales of the product. Because of the long term nature of these projects, we may recognize revenues from milestone payments or royalties in one period and the associated expenses in prior periods. The principal expense of this business is research and development expense, which consists primarily of labor costs, raw material expenses, third-party consulting and testing costs and costs for clinical trials. In some cases, these costs may be directly reimbursed by our customers. For fiscal years 2004, 2003 and 2002, our expenditures on research and development were $16.4 million, $21.8 million and $20.9 million, respectively. Due to liquidity constraints, we anticipate that 2005 expenditures on research and development will significantly decline. During 2004, net revenues of our product development business unit were $24.0 million, or 11% of our consolidated net revenues, of which $17.7 million was attributable to our significant development agreement discussed below.

Product Acquisitions

Since August 2001, we have acquired the M.V.I. and Aquasol product lines from AstraZeneca, our Brethine product line from Novartis, our Darvon and Darvocet product lines from Eli Lilly, our Darvocet A500 product from Athlon Pharmaceuticals and our Roxicodone, Oramorph SR, Roxanol and Duraclon pain management products from Elan Corporation, plc. Each of these acquisitions were made with cash consideration largely financed by the incurrence of debt. For a description of these acquisitions, including more detailed information on the issuance of debt in connection with these acquisitions, see Note 2 of Notes to Consolidated Financial Statements included elsewhere in this report.

42

Significant Product Disposition

On April 26, 2004, we sold our M.V.I. and Aquasol product lines to Mayne Pharma (USA) Inc. for $105 million, subject to adjustments based on inventory levels at closing and other post-closing obligations. Of that amount, $10 million was held in escrow to satisfy our post-closing obligations under the agreement. In September 2004, approximately $1.6 million of this escrowed amount was paid to us. We do not anticipate receiving any additional payments out of this escrow. In addition, we are entitled to royalties on sales levels, above specified thresholds, of the M.V.I. line extension product that does not contain vitamin K, which we developed. At the closing of the transaction, we paid to AstraZeneca AB a $31.5 million payment due in August 2004 that was required to be paid upon FDA approval of a reformulated MVI Product pursuant to the terms of the agreement pursuant to which we acquired MVI and Aquasol. The payment was discounted to approximately $31.0 million. The sale resulted in a gain of $39.1 million that we recorded in the second and third quarters of 2004. The gain was partially offset by the $31.0 million expense we recorded in the first quarter of 2004 for the contingent payment to AstraZeneca AB.

Special Committee Investigation

On February 27, 2004, our Board of Directors appointed a committee consisting of all of the non-employee members of our Board of Directors (the “Special Committee”) to conduct an inquiry into unusual sales in our Brethine and Darvocet product lines. King & Spalding LLP, an independent law firm, and Deloitte & Touche USA LLP, as independent forensic accountants, were engaged to assist the Special Committee in this inquiry.

In connection with the Special Committee’s inquiry, we determined that certain matters required material adjustments to the 2003 financial information included in our February 5, 2004 press release and the financial information for the periods ended March 31, June 30, and September 30, 2003.

In addition to the accounting treatment adjustments identified in connection with the Special Committee’s investigation, we identified several other adjustments that affected the 2003 financial information that we had included in our February 5, 2004 press release. These adjustments included:

	•	a charge of $15.9 million due to the impairment of our Brethine intangible asset recorded in the fourth quarter of 2003;
	•	a $4.7 million impairment charge in the fourth quarter of 2003 which represents the entire intangible asset recorded in the third quarter of 2003 relating to the acquisition of Darvocet A500;
	•	a $7.3 million increase in our returns reserve for sales of Brethine and Darvon/Darvocet products in the fourth quarter of 2003;
	•	a $2.7 million increase in our inventory obsolescence reserve in the fourth quarter of 2003;
	•	a $3.2 million increase in our chargeback reserve for sales in the fourth quarter of 2003 for our Oramorph product and other products; and

43

•

a valuation allowance of $10.0 million as an offset against our deferred tax asset as of December 31, 2003.

In addition to the 2003 adjustments arising in connection with the Special Committee’s investigation and the additional adjustments identified above, as previously reported, we restated our financial statements for the year ended December 31, 2002 and for the periods ended March 31, June 30, and September 30, 2002 and 2003 to treat each of our major product line acquisitions as acquisitions of assets that do not constitute a business.

As a result of the foregoing, in our Annual Report on Form 10-K for the year ended December 31, 2003, we reduced our 2003 net revenues and diluted earnings per share by $57.7 million and $2.35, respectively, from the results we reported in our February 2004 press release. In addition, we reduced our 2002 diluted earnings per share by $0.15 from the results reported in our Annual Report on Form 10-K for the year ended December 31, 2002.

Significant Development Agreement

We have a development agreement with a customer that provides for us to receive contingent periodic royalties based on sales of the customer’s product and obligates the customer to use us on a fee-for-service basis for a product life cycle management project related to the product. The customer is a major pharmaceutical company with net assets in excess of $2.0 billion. The development agreement relates to a product with respect to which we have licensed intellectual property that we developed in the past. We have recognized product development revenues under this agreement for the periodic payments based on our customer’s sales of the product and have recognized development services revenue related to the product life cycle management project. In April 2004, we entered into an agreement to receive a prepayment of the remaining product development amounts under this agreement which would otherwise be paid to us quarterly through the second quarter of 2005. These payments would have aggregated $15.4 million. Our agreement to receive a prepayment of these amounts applied a 5% per annum discount from the date the payment would otherwise be due to the date paid. In April 2004, we received approximately $15.0 million in gross proceeds from prepayments made pursuant to this agreement.

Product development revenues from this agreement were $17.7 million in 2004, $13.0 million in 2003 and $16.9 million in 2002. We recognized no research and development expense in 2004, 2003 and 2002 associated with the payments we received in those years. The expense of our work associated with these revenues was recognized primarily in 1997 through 1999. We do not anticipate that we will receive any further product development payments in connection with this significant development agreement in the future. Our obligations under the significant development agreement with respect to the prepaid amounts continue through the second quarter of 2005, and we will recognize approximately $7.0 million of revenue in the first half of 2005 associated with the prepayment received in April 2004 as we satisfy these contractual obligations through the second quarter of 2005.

The development agreement also required the customer to use a minimum amount of our development services at standard rates on the product life cycle management project. In 2004, 2003 and 2002, the project was at the minimum contractual levels. Development services

44

revenues associated with this agreement were $0.7 million in 2004, $2.7 million in 2003 and $4.7 million in 2002. We have recorded our costs incurred in this project as research and development expense—zero in 2004, $1.0 million in 2003 and $0.7 million in 2002. Accordingly, for our development services business unit, we have recognized no expense associated with the development services revenue arising under this agreement, as this expense was recognized by our product development business unit. The customer is not obligated to continue the project after December 2004, and we do not anticipate any further development services revenue from this project.

2004 Financial Summary

In 2004, we recorded net revenues of $215.3 million and a net loss of $191.2 million or $(6.69) per share. Our consolidated net revenues for 2004 decreased from 2003 as a result of a significant decrease in pharmaceutical product sales. The decrease resulted from decreased sales volumes in our Darvon/Darvocet and Brethine product lines, which were affected by the amount of inventory previously sold into the wholesale channel, as well as the divestiture of our M.V.I. and Aquasol product lines in the second quarter of 2004, as partially offset by contributions from our Roxicodone and Oramorph product lines, which were acquired in December 2003.

The following table presents the net revenues for each of our major pharmaceutical product lines:

Several events occurred which had a material impact on our financial results. We recorded an $87.1 million charge in December 2004 due to the impairment of intangible assets associated with our Darvon/Darvocet products and we recorded charges of $6.4 million in the second half of 2004 due to the impairment of an intangible asset associated with our Brethine product. These impairment charges will not result in future cash expenditures.

In 2004, we announced and implemented several restructuring plans, and recorded charges of $22.4 million related to work force reductions and facility closures. These charges included severance costs and related employee-benefit expenses, separation payments to our former chief executive officer and costs for leased facilities which are no longer in use. We recorded $11.0 million of legal, financial and consulting professional fees in 2004 associated with a previously disclosed internal investigation conducted by a Special Committee of our Board of Directors.

In April 2004, we sold our M.V.I. product lines to Mayne Pharma (USA) Inc. The sale resulted in a gain of $39.1 million that we recorded in the second and third quarters of 2004. The gain was partially offset by a $31.0 million expense we recorded in the first quarter of 2004 for a

45

contingent payment to AstraZeneca AB based on the regulatory approval of the reformulation of our M.V.I.-12 product.

In addition, in the fourth quarter of 2004, we recorded a charge of $11.7 million, and established a corresponding reserve, related to a pharmaceutical product manufacturing supply agreement entered into in 2003 requiring us, subject to the terms and conditions of the agreement, to purchase a minimum level of certain products on a take-or-pay basis by September 2006. We are negotiating with the manufacturer under this agreement to extend the term of our obligation to purchase the minimum level of products by an additional multi-year period and to include additional products to be manufactured for us under this agreement and applied against our minimum purchase requirement. If we are successful in amending the agreement on this basis, the reserve and corresponding charge may be reversed in a subsequent period. We cannot provide any assurance, however, that we will be successful in amending the agreement on any terms.

Operating results for our product sales business continued to be affected by the amount of inventory previously sold into the wholesale channel. Our revenues from sales to wholesalers in 2004 were significantly reduced from prior periods due to the levels of Brethine and Darvon/Darvocet products on hand at wholesalers at the beginning of the year. During 2004, we reduced the aggregate amount of units of our products at the wholesalers and chain pharmacies by approximately 73%. This inventory comparison excludes M.V.I. and Aquasol product (which we sold in April 2004) at all relevant times. As part of our effort to reduce inventories in the distribution channel, we stopped offering negotiated discounts to our wholesalers with respect to sales of pharmaceutical products, which we believe lowered wholesale demand. We believe that wholesalers have recently limited, and may continue to limit, their purchases of pharmaceutical products from us to minimize any exposure that could result from our liquidity position. We recognized $77.8 million in pharmaceutical product revenues in 2004. Of that amount, we recognized $10.5 million in revenues recorded under the consignment method. For these revenues, we had received cash for the products from the wholesalers, principally in late 2003 or in the first quarter of 2004. The introduction of generic competition to our Brethine injectable and Roxicodone products also had a negative impact on sales.

During 2004, one of our major pharmaceutical product customers ceased making cash payments to us for pharmaceutical products that it purchased as a set-off for amounts that we currently owe under separate agreements with its affiliates and for amounts we may owe related to chargebacks and returns exposure to such customer and its affiliates. We continue to conduct business with this customer and its affiliates.

Our AAI Development Services Division recorded $94.9 million in net revenues during 2004. In 2004, we continued to experience strong demand for Phase I services in both the United States and Europe, as well as for analytical services. The AAI Development Services Division was able to dedicate more capacity to outside clients during 2004 due to reduced utilization of resources on internally driven research and development projects. Notwithstanding increased demand in 2004 in the development services business, customer concerns with respect to our uncertain financial condition are adversely affecting our ability to obtain new development service projects, particularly long-term projects. This trend, if it were to continue, could adversely affect

46

future period net revenues of our AAI Development Services Division. The manufacturing capacity for the Charleston facility was planned to cover the manufacturing needs of our Brethine injectable product. The introduction of a generic competitor eliminated the near-term need for manufacturing additional Brethine injectable products and created for us an excess in sterile manufacturing capacity which we were not able to sell to third parties.

During 2004, we recorded $16.3 million in research and development expenses. However, due to liquidity constraints, we do not believe we will be able to fund additional research and development activities in 2005 at this level, we have significantly reduced research and development expenditures in 2005 and we may not be able to fund additional research and development activities at all.

Results of Operations

The following table presents the net revenues for each business unit we operated in 2004 and our consolidated expenses and net (loss) income and each item expressed as a percentage of consolidated net revenues:

47

Year Ended December 31, 2004 Compared to Year Ended December 31, 2003

Our consolidated net revenues for the year ended December 31, 2004 decreased 9% to $215.3 million, from $236.9 million in 2003. Net revenues from product sales decreased 35% in 2004 to $77.8 million, from $119.2 million in 2003. The decrease resulted from decreased sales volumes in our Darvon/Darvocet and Brethine product lines, as discussed above, as well as the divestiture of our M.V.I. and Aquasol product lines in the second quarter of 2004, which was partially offset by contributions from our Roxicodone and Oramorph product lines. Roxicodone and Oramorph were acquired in December 2003. In addition, the price of our Brethine product decreased significantly in 2004 due to the introduction of generic competition. In June 2004, we exchanged products that were nearing expiration with products with improved expiry dating at one wholesaler which reduced our returns reserve requirements by $3.9 million. This reduction is reflected as an increase in net revenues in 2004. Our net revenues for the year ended December 31, 2004 and 2003 included $10.5 million and $13.9 million, respectively, recognized under the consignment sales method.

Net revenues from product development increased 46% in 2004 to $24.0 million, or 11% of net revenues, from $16.5 million, or 7% of net revenues, in 2003 period, primarily due to product development revenues under our significant development agreement, a milestone payment related to FDA approval of a new drug application for Aventis’ new Allegra-D 24 hour tablets, and a payment from SICOR Pharmaceuticals Inc. to reacquire their U.S. marketing rights for calcitriol. We expect to record net revenues of $7.0 million under our significant development agreement in 2005, although we received the cash associated with this revenue in April 2004, and we do not expect any further cash receipts or revenues under this agreement.

Net revenues from our development services business increased 6% in 2004 to $94.9 million, from $89.3 million in 2003. The increase was principally attributable to higher demand for our Phase I clinical capabilities in both the United States and Europe, as well as for Phase II-IV and bioanalytical services, partially offset by lower fee-for-service revenues under our significant development agreement.

Reimbursed out-of-pocket revenues represent out-of-pocket expenses we incur that are reimbursed to us by our clients. Reimbursed out-of-pocket revenues increased to $18.7 million in 2004, from $12.0 million in 2003. This increase is primarily related to projects in our clinical trials operations and is expected to fluctuate from one period to another as a result of changes in the clinical trials conducted during any period of time.

Direct costs (excluding depreciation and royalty expense) decreased $5.9 million, or 5%, to $120.9 million in the year ended December 31, 2004, from $126.8 million in the same period in 2003. This decrease in direct costs resulted primarily from lower unit sales of our pharmaceutical products, partially offset by an increase in reimbursable out-of-pocket expenses. Direct costs as a percentage of net revenues were 56% in 2004 as compared to 54% in 2003.

48

Selling expenses decreased 12% in 2004 to $35.0 million, or 16% of net revenues, from $39.5 million, or 17% of net revenues, in 2003. This decrease is primarily due to reduced personnel and marketing and promotional costs related to our product sales business partially offset by increases associated with sales force related expenses under an agreement with Athlon Pharmaceuticals. We terminated the contract with Athlon for our outside sales force in the second quarter of 2004 and we terminated our entire internal sales force in the fourth quarter of 2004. As of December 31, 2003, our pharmaceutical sales force was approximately 200, including 105 outside sales professionals provided under the contract with Athlon.

General and administrative costs increased $5.4 million in 2004 to $45.9 million, or 21% of net revenues, from $40.5 million, or 17% of net revenues, in 2003. This increase was primarily due to additional product liability insurance expense for the products we acquired in December 2003 and litigation-related expenses. During 2004, we incurred legal fees and expenses in our ongoing omeprazole patent litigation against Schwarz Pharma Inc., Schwarz Pharma AG, Kremers Urban Development Co., and certain of their affiliates. We anticipate that we will continue to incur legal fees and expenses in connection with this litigation in 2005, as well as other litigation and investigations. See Part I, Item 3 “Legal Proceedings” for additional information regarding this litigation and other pending litigation that may significantly increase our legal expenses in 2005.

Research and development expenses were $16.3 million, or 8% of net revenues, in 2004, compared to $21.8 million, or 9% of net revenues, in 2003. The decrease in research and development expenses was primarily attributable to the liquidity issues we faced in 2004. Significant project spending in 2004 was related to our Lynxorb (formerly referred to as ProSorb-D) pain management product and our proton pump inhibitor development program.

In 2004, we recorded $11.0 million of legal, financial and consulting professional fees associated with the investigation conducted by the Special Committee. We will continue to incur significant legal, financial and consulting professional fees in 2005 associated with debt restructuring activities, including costs related to a potential filing under Chapter 11 of the U.S. Bankruptcy Code.

In April 2004, we sold our M.V.I. and Aquasol product lines to Mayne Pharma (USA) Inc. for $105 million, subject to certain adjustments and an escrow of part of the purchase price. The sale resulted in a gain of $39.1 million that we recorded in the second and third quarters of 2004. The gain was partially offset by a $31.0 million expense we recorded in the first quarter of 2004 for a contingent payment to AstraZeneca AB based on the status of the reformulation of our M.V.I.-12 product. The FDA’s approval in the first quarter of the reformulation of this product created an obligation under our product line acquisition agreement for us to make this contingent payment.

In the fourth quarter of 2004, we recorded a charge of $11.7 million, and established a corresponding reserve, related to a pharmaceutical product manufacturing supply agreement entered into in 2003 requiring us, subject to the terms and conditions of the agreement, to purchase a minimum level of products on a take-or-pay basis by September 2006. We do not expect to be able to fulfill our purchase obligations under this agreement within that period. We are negotiating with the manufacturer under this agreement to extend the term of our obligation

49

to purchase the minimum level of products by an additional multi-year period and to include additional products to be manufactured for us under this agreement and applied against our minimum purchase requirement. If we are successful in amending the agreement on this basis, the reserve and corresponding charge may be reversed in a subsequent period. We cannot provide any assurance, however, that we will be successful in amending the agreement on these, or any other, terms.

In 2004, we announced and implemented several restructuring plans, which included work force reductions and facility closures. We recorded a $22.4 million expense in 2004, primarily representing severance costs and related employee-benefit expenses of $5.5 million, separation payments of $1.9 million to our former chief executive officer and costs of $15.0 million for assets and leased facilities which are no longer in use. These leased facilities include our New Jersey lab facility, smaller facilities in North Carolina, Florida and California, and aircraft leased by us. We are currently seeking to sub-lease these facilities, and have entered a short-term sublease for one aircraft and the California facility.

Royalty expenses for the year ended December 31, 2004 were $1.7 million. We accrued royalties based on revenues generated by certain acquired products, including calcitriol injectable, which we divested in December 2004. We will continue to incur royalty expenses on other products in 2005. Royalty expenses were $1.1 million for 2003.

In September and December 2004, we recorded charges of $5.3 million and $1.2 million, respectively, due to the impairment of an intangible asset associated with our acquired Brethine product. The introduction of generic competition for our Brethine injectable product affected our future anticipated revenues, which negatively impacted the carrying value of the acquired intangible assets. In December 2004, we also recorded an $87.1 million charge due to the impairment of intangible assets associated with our Darvon/Darvocet products. This charge resulted from the impact on our impairment analysis of our experience in the process we undertook to sell the Darvon/Darvocet products.

Our consolidated loss from operations was $144.1 million in 2004, as compared to $21.3 million in 2003. This decrease is primarily attributable to the intangible asset impairment charges and the other items discussed above, including the decrease in product sales revenue, higher general and administrative expenses, professional fees related to the Special Committee investigation, and the restructuring charges, partially offset by the higher development services and product development revenues, lower selling expenses and the gain on the sale of the M.V.I. and Aquasol product lines, net of the expenses associated with the M.V.I. Contingent Payment.

The loss from operations for our product sales business was $108.6 million in 2004, compared to income from operations of $1.7 million in 2003. This decrease is attributable to a decrease in revenue due to the divestiture of our M.V.I. and Aquasol product lines, the reduction in sales volumes of our Darvocet and Brethine products, the introduction of generic competition for our Brethine and Roxicodone products, the intangible asset impairment and guaranteed purchase commitment charges, both as discussed above, and restructuring charges of $3.1 million.

50

Income from operations for our product development business was $24.0 million in 2004, compared to income from operations of $16.5 million in 2003. This change resulted from the increased revenues from our significant development agreement, as discussed above.

The loss from operations for our development services business was $3.6 million in 2004, compared to income from operations of $1.7 million in 2003. This change is primarily due to restructuring charges of $10.8 million, as discussed above, partially offset by the higher revenues.

Unallocated corporate expenses increased in 2004 to $38.7 million, from $19.0 million in 2003. This increase is primarily related to restructuring charges of $8.0 million and the $11.0 million of professional fees related to the Special Committee investigation.

Net interest expense increased to $35.0 million in 2004 from $21.1 million in 2003 due to charges related to the refinancing of our senior credit facilities (see “Liquidity and Capital Resources” for additional information on changes to our debt). In addition, we recorded a $6.2 million expense for the extinguishment of debt related to our previous senior credit facilities.

Other expense in 2004 includes $1.6 million representing the fee we paid to terminate an agreement we had entered into to purchase a product awaiting regulatory approval that we subsequently concluded was no longer commercially viable. Terminating the agreement eliminated a contingent payment obligation of $13.8 million. No future obligations remain under this terminated agreement.

Other income in 2003 included $5.6 million related to the termination fee, net of expenses, received from CIMA Labs Inc. in connection with CIMA’s termination of a merger agreement with us, and the $1.8 million gain from the sale of our investment in Endeavor Pharmaceuticals Inc., a pharmaceutical development company which we helped organize in 1994.

We recorded income tax expense of $3.7 million in 2004. We currently believe that it is more likely than not that any deferred tax assets generated during 2004 will not be utilized; therefore no tax benefit was recorded. Included in this tax expense is an additional valuation allowance for previously unreserved deferred tax assets for which it is now more likely than not that the benefit will not be realized. The need for this additional valuation allowance resulted from changes in the projected recoverability of these deferred tax assets. Our effective tax rate for 2004 was 2%. Our effective tax rate for 2003 was 12%.

Year Ended December 31, 2003 Compared to Year Ended December 31, 2002

Our consolidated net revenues for the year ended December 31, 2003 decreased 2% to $236.9 million, from $241.2 million in 2002. The decrease was attributable to lower net revenues recorded from the sale of our pharmaceutical products and, to a lesser extent, a reduction in product development revenues associated with our significant development contract.

Net revenues from product sales decreased to $119.2 million in 2003, from $124.4 million in 2002. The decrease in net revenue was attributable to reduced net sales of our Brethine line and, to a lesser extent, reduced net sales of our M.V.I. line.

51

These reduced sales were mitigated in 2003 by the introduction of several new products, including the New Pain Products acquired from Elan in December 2003, our Darvocet A500 line extension introduced in September 2003 and our calcitriol injection product introduced in March 2003. These new product offerings contributed an aggregate of $17.4 million to 2003 net revenue, of which $14.5 million was attributable to sales of the New Pain Products. In addition, price increases, primarily related to our Brethine injectable product and Darvon and Darvocet product lines, accounted for $9.5 million of our 2003 net revenue.

Net revenues from product development decreased 16% in 2003 to $16.5 million, or 7% of net revenues, from $19.6 million, or 8% of net revenues, in 2002, primarily due to lower revenues related to our significant development agreement in 2003 and to third-party licensing payments which we had previously deferred and were amortized into revenue in 2002 and prior years. No previously deferred revenues were recognized in 2003.

Net revenues from our development services business increased 3% in 2003 to $89.3 million, from $86.5 million in 2002. This increase was principally attributable to higher demand for our European bioanalytical and clinical services and our U.S. analytical capabilities, partially offset by lower fee-for-service revenues from lower demand for our clinical manufacturing and formulations services and under our significant development agreement.

Direct costs (excluding depreciation and royalty expense) increased $25.4 million, or 25%, to $126.8 million in 2003, from $101.4 million in 2002. This increase in direct cost dollars resulted from higher product costs of $8.8 million, increased inventory reserves of $11.2 million related to estimated reserves for excess wholesaler inventories in excess of anticipated demand in 2003 and increased amortization expense of $3.0 million related to product rights for acquired products. Direct costs as a percentage of net revenues increased to 54% in 2003 from 42% in 2002.

Selling expenses increased 71% in 2003 to $39.5 million, or 17% of net revenues, from $23.1 million, or 10% of net revenues, in 2002. This increase is primarily due to expenses incurred by our product sales business associated with developing our product sales force and marketing and promoting our new products. As of December 31, 2003, our pharmaceutical sales force was approximately 200, including 105 outside sales professionals added in October 2003 under an agreement with Athlon Pharmaceuticals, from whom we acquired our Darvocet A500 product, as compared to 50 sales professionals at December 31, 2002.

General and administrative costs increased 1% in 2003 to $40.5 million, or 17% of net revenues, from $40.1 million, or 17% of net revenues, in 2002. This increase was primarily due to additions to our corporate infrastructure to accommodate the expansion of our overall business, expenses related to the management build-up for our product sales business and increased product related insurance costs, partially offset by lower legal fees and employee benefit related expenses.

Research and development expenses increased 4% in 2003 to $21.8 million from $20.9 million in 2002. These amounts represented 9% of net revenues in 2003 and 2002. We incurred significant project spending in 2003 related to our ProSorb-D pain management product and development work on line extensions for our pain management and critical care products.

52

Royalty expenses in 2003 were $1.1 million. We accrue royalties based on revenues generated by certain acquired products, including our Darvocet A500 product and our calcitriol product. No similar royalty expenses were incurred in 2002.

In December 2003, we recorded a $15.9 million charge due to the impairment of an intangible asset associated with our acquired Brethine product. The then-anticipated introduction of generic competition for this product (which subsequently occurred in May 2004) affected our future anticipated revenues, which negatively impacted the carrying value of the acquired intangible assets. We also recorded a $4.7 million write down of the full amount of the intangibles assets related to the Darvocet A500 product we acquired in 2003. In March and April of 2004, we experienced significant requests for returns of Darvocet A500. We re-evaluated our sales forecast for Darvocet A500 and identified a potential impairment of the asset. As a result of the impairment analysis, we determined that the asset needed to be written-off.

The consolidated loss from operations was $21.3 million in 2003, compared to consolidated income from operations of $48.6 million in 2002. This decrease was primarily due to the lower product sales and product development revenues in 2003, increased product-related costs and the intangible asset impairment charges.

Income from operations for our product sales business in 2003 was $1.7 million, compared to $66.4 million in 2002. This decrease resulted from the combination of reduced net sales, increases in our reserves for product returns, increased sales costs associated with the launch of Darvocet A500, and the intangible asset impairment recorded in the fourth quarter.

Income from operations for our product development business was $16.5 million in 2003, compared to income from operations of $19.6 million in 2002. This change resulted from the decreased revenues from our significant development agreement.

Income from operations for our development services business was $1.7 million in 2003, compared to $1.0 million in 2002. This increase is primarily due to increased margins in our bioanalytical and analytical businesses in 2003. The increase in revenues was the primary reason for the higher operating margins achieved in 2003.

Unallocated corporate expenses increased in 2003 to $19.0 million, or 8% of net revenues, from $17.2 million, or 7% of net revenues, in 2002. This higher level was due to additions to our corporate infrastructure to accommodate the expansion of our overall business.

Net interest expense increased to $21.1 million in 2003, from $19.4 million in 2002. This $1.7 million increase is primarily attributable to the borrowings that funded our product line acquisitions in December 2003 and March 2002, partially offset by debt repayments and lower interest rates on our variable rate debt.

Losses from the extinguishment of debt of $1.5 million and $8.1 million were recorded in 2003 and 2002, respectively. These losses resulted from the write-off of deferred financing and other costs due to the refinancing of our term loan facility in December 2003 in connection with our New Pain Products acquisition and the refinancing of our prior debt facilities in March 2002 related to our Darvon and Darvocet acquisition.

53

Other income in 2003 included $5.6 million related to the termination fee, net of expenses, received from CIMA Labs Inc. in connection with CIMA’s termination of a merger agreement with us, and the $1.8 million gain from the sale of our investment in Endeavor Pharmaceuticals Inc., a pharmaceutical development company which we helped organize in 1994.

We recorded a tax benefit of $4.5 million in 2003, based on an effective tax rate of 39%, offset by a valuation allowance of $10.0 million because it is more likely than not that some portion of the deferred tax asset will not be realized. Our effective tax rate for 2002 was 39%.

Liquidity and Capital Resources

Liquidity was a major focus of management attention throughout 2004. We replaced our senior credit facilities in April 2004 and increased the size of such facilities from $140 million to $180 million through a series of amendments during 2004 to meet liquidity needs, including the payment of the interest due on our senior subordinated notes. We also amended our senior subordinated notes and received consents of the holders thereof to waive certain defaults and facilitate the senior debt facility amendments. See “—Senior Credit Facilities” and “—Subordinated Notes due 2010” below. In addition, we implemented reductions in workforce and facility closure plans to rationalize our expense base as it relates to revenues, resulting in $22.4 million of restructuring plan charges, and we disposed of certain investments and non-core assets for liquidity purposes in addition to the sale of our M.V.I. and Aquasol product lines described below.

Because of the potential for defaults under our senior credit facilities and notes at December 31, 2004, including failure to pay the interest on our Notes due April 1, 2005, all $350.5 million of debt outstanding at December 31, 2004 under our senior credit facilities and notes is classified as current liabilities on our consolidated balance sheet at December 31, 2004. Due in part to this classification, our current liabilities at December 31, 2004 exceed our current assets by $385.2 million.

In light of our current financial condition, we believe that our operations cannot support our existing debt and that we must restructure our debt to levels that are more in line with our operations. Thus, it is highly likely that we will seek relief in bankruptcy under chapter 11 of the Bankruptcy Code. See “—Analysis of Liquidity” below.

Historically, we have funded our businesses with cash flows provided by operations and proceeds from borrowings. Cash flow used in operations in 2004 was $93.1 million, compared to cash flow provided by operations of $38.4 million in 2003. This decrease was primarily due to a significant decrease in cash receipts from the sale of our pharmaceutical products, a significant increase in cash expenditures for professional fees, and a decrease in deferred revenues on products accounted for under the consignment model, partially offset by a significant decrease in the gross amount of our accounts receivable. In the second half of 2004, we also reclassified $12.4 million from deferred product revenue to other accrued liabilities, recognizing the potential return of certain products accounted for under the consignment model resulting from reduced demand and related expiration issues.

54

The gross amount of our accounts receivable decreased by $45.8 million, or 53%, in 2004 due to significant collections in 2004 for pharmaceutical products shipped during the fourth quarter of 2003 and a significant decrease in the amount of pharmaceutical products shipped during 2004. This decrease in our accounts receivable was partially offset by the effect of the decision of one of our major pharmaceutical products customers to setoff cash payments due to us for certain pharmaceutical products that it purchased from us against amounts due from us for services under separate agreements with affiliates of such customer. This customer also has setoff cash payments due to us against amounts that we may owe it for product returns and chargebacks related to certain pharmaceutical products that it has already purchased from us. We are in on-going negotiations with this customer regarding these payments and setoffs.

Additionally, as of December 31, 2004, our $39.9 million in gross accounts receivable were offset by $24.6 million in allowances for customer credits, which primarily consist of reserves we established to cover estimated future chargebacks and estimated future product returns. These reserves are necessary because we must either issue a credit on future sales or make a cash payment when a chargeback is issued or when wholesalers exercise their rights of return for our pharmaceutical products as the products near expiration.

Cash provided by investing activities was $87.2 million in 2004, primarily related to the cash proceeds from the sale of our M.V.I. and Aquasol product lines, partially offset by $5.4 million of capital spending. Cash used in investing activities was $114.3 million in 2003, which included $102.5 million related to our pain product acquisition in December 2003 and $11.9 million related to capital spending.

Net cash provided by financing activities during 2004 was $4.4 million, primarily representing $177.5 million of borrowings under our senior credit facilities and $3.4 million in proceeds from the issuance of common stock primarily related to the exercise of stock options, partially offset by debt repayments of $166.0 million under the previous debt agreements and a termination payment of $9.4 million under our previous interest rate hedging agreement.

Net cash provided by financing activities during 2003 was $78.0 million, primarily representing net proceeds of $160.0 million in additional borrowings under the term loan facility we entered into in December 2003, as described below, $8.8 million of cash proceeds from the exercise of stock options and $1.7 million related to the unamortized proceeds from the sales of our interest rate swap, partially offset by the repayment of $93.5 million of borrowings under the then-existing revolving credit facility and the prior term loan credit facility. These repayments included $50.0 million from the proceeds of the term loan we entered into in December 2003. The additional repayments were funded by cash from operations as part of our program to aggressively pay down our then-existing credit facility. These prepayments of our term loan indebtedness reduced our liquidity.

M.V.I. and Aquasol Product Line Sale and Contingent Payment

The agreement under which we acquired our M.V.I. and Aquasol product line was amended in July 2003. As amended, it provided for two $1.0 million guaranteed payments, which were made in August 2002 and 2003, eliminated a contingent payment of $2.0 million that was potentially due in August 2003 under the original agreement, and provided for a future

55

contingent payment of $43.5 million, which we refer to as the M.V.I. Contingent Payment, potentially due in August 2004, depending on the status of certain reformulation activities being carried out by the seller and regulatory approval of the reformulations by the U.S. Food and Drug Administration (FDA). The amount of the M.V.I. Contingent Payment was to be reduced by $1 million per month if the conditions for the contingent payment had not occurred by December 31, 2002. The amount of the M.V.I. Contingent Payment had decreased by $12.0 million by December 31, 2003. Such conditions were satisfied in January and February 2004, fixing the previously contingent liability under the amendment at $31.5 million. As a result of an amendment to the original acquisition agreement, we were precluded from recognizing this obligation as additional purchase price for the M.V.I. and Aquasol product line; therefore, we expensed this obligation in the first quarter of 2004. We sold the M.V.I. and Aquasol product lines on April 26, 2004. Because the $31.5 million contingent payment was not included in the basis of the assets sold, we recorded a gain from the sale transaction in the second quarter of 2004 of $37.5 million, which was partially offset by the expense for the M.V.I. Contingent Payment in the first quarter of 2004. We made the M.V.I. Contingent Payment, discounted to approximately $31.0 million, in April 2004. In the third quarter of 2004, we recorded an additional gain of $1.6 million related to a reduction in our post-closing obligations under the purchase agreement.

Senior Credit Facilities

On April 23, 2004, we entered into $140 million of senior credit facilities with a syndicate of lenders, Silver Point Finance LLC (“Silver Point”) as collateral agent, and Bank of America, N.A., as administrative agent. We entered into amendments to these credit facilities on August 9, 2004 and August 13, 2004 to, among other things, increase the amount of the term loan by up to $10 million, extend the maturity date of the facilities by one year, increase the interest rate on the loans by an additional 1.5% subject to potential incremental reduction, adjust certain covenants under the facilities and waive certain defaults and events of default. As amended, our new senior credit facilities consisted of a $135 million senior secured term loan facility (of which $125 million was fully drawn at the initial closing in April and the remaining $10 million was drawn on August 13, 2004) and a $15 million senior secured revolving credit facility. Our senior credit facilities included a covenant requiring us to maintain combined availability under the revolving credit facility and cash and cash equivalents in the aggregate amount of $5.0 million plus certain other amounts related to payables, bank overdrafts and interest payments on the loans paid in the form of additional notes. The outstanding loans under our new senior credit facilities are payable in full on April 21, 2007. The August amendments also required us to retain FTI Consulting, Inc. during the term of the senior credit facilities unless certain available cash and annualized cost reduction thresholds were satisfied by a specific date, at which time our retention of FTI could be terminated. These thresholds were not met.

Our senior credit facilities are secured by a security interest on substantially all domestic assets, all of the stock of domestic subsidiaries and 65% of the stock of material foreign subsidiaries. As part of the initial borrowing under these senior credit facilities, we recorded a $6.2 million loss for the early extinguishment of debt related to the write-off of financing fees related to our previous senior credit facilities. Subject to exceptions set forth in the definitive documentation, loans under our new senior credit facilities are also required to be prepaid with a negotiated percentage of:

56

	•	excess cash flow, as defined;
	•	non-ordinary course assets sales;
	•	net proceeds from the sale of subordinated indebtedness;
	•	net proceeds from equity issuances; and
	•	extraordinary receipts, as defined.

Optional reductions in revolving credit commitments and optional prepayments of term loans, as well as mandatory reductions in revolving credit commitments and mandatory prepayments of term loans from the net proceeds of asset sales, subject to defined exceptions, are subject to a prepayment fee equal to 3.5% until August 9, 2005, 2.5% for the subsequent 12 months, and 1.5% for the next 6 months (with no prepayment penalty payable for the remainder of the term). Prior to the August 9, 2004 amendment, outstanding loans under the facilities bore interest at a rate per annum equal to a defined LIBOR rate (with a floor of 2%), plus 6.25%, or a defined reference rate (with a floor of 4%), plus 5.25%, in each case payable monthly in arrears. As a result of, and effective with, the August amendments to these credit facilities, the applicable interest rate on outstanding loans was increased by an incremental amount, which was initially 1.5%, subject to incremental reductions based on our financial performance. An additional 1% per annum unused line fee is payable on unused revolving credit commitments, payable quarterly in arrears.

The proceeds of the initial borrowings under these facilities were used, together with the net cash proceeds from the sale of our M.V.I. and Aquasol product lines, to (i) fund payment of termination obligations with respect to our interest rate hedging agreement (discussed below), (ii) refinance our then-existing senior credit facilities, (iii) fund the April 2004 interest payment due on our senior subordinated notes due 2010, (iv) provide for ongoing working capital and general corporate needs, and (v) pay fees, costs and expenses in connection with the new senior credit facilities and other corporate transactions.

Effective as of October 8, 2004, we amended our senior secured credit facilities to, among other things, adjust financial covenants. The senior secured lenders also waived compliance with certain financial covenants in the senior secured credit facility for the quarter ended September 30, 2004 and the quarter ended December 31, 2004 provided that we met minimum consolidated EBITDA thresholds (as defined in the senior secured credit facility). The amendment also added a minimum gross revenue requirement of $40 million for the quarter ended December 31, 2004 and consented to certain asset disposition transactions and receipt of a deferred purchase price payment pursuant to which we received approximately $4.2 million in the aggregate. These transactions related to the sale of our investment in Aesgen and our M.V.I. and Aquasol product lines. The amendment also waived any requirement to prepay the senior secured loans with the net proceeds of these transactions. As a result of changes to certain financial covenants affected by this amendment, we were in compliance with the adjusted covenants under our senior credit facilities at and for the applicable periods ended December 31, 2004.

On October 22, 2004, we entered into another amendment to our senior secured credit facility that increased the existing term loan facility under our senior secured credit facility by $30 million (the “Supplemental Term Loan”), subject to certain specified conditions which were satisfied on October 29, 2004. The Supplemental Term Loan was made available in up to three draws to be made on or prior to January 15, 2005. We borrowed $20 million of such term loans

57

on October 29, 2004 and the remaining $10 million of such loans in increments on November 5, 2004, November 12, 2004, November 24, 2004 and December 9, 2004. Following effectiveness of the amendment and these borrowings, our senior secured credit facility consisted of a term loan of $165 million and a revolving credit facility of up to $15 million.

The amendment also modified the interest rate on the entire senior secured credit facility, including the Supplemental Term Loan, to equal a defined LIBOR rate (with a floor of 2%) plus 8.25% per annum or a defined reference rate (with a floor of 4%) plus 7.25% per annum. The amendment also provided for a commitment fee equal to 0.75% per annum on any undrawn portion of the Supplemental Term Loan, payable monthly in arrears. At December 31, 2004, 30-day LIBOR was 2.4%.

The amendment retained the April 21, 2007 maturity date of the senior secured credit facility and the optional and mandatory prepayment requirements and premiums described above.

The proceeds of the loans under the Supplemental Term Loan were used (i) to fund payment of the October 1, 2004 interest payment due on our senior subordinated notes, (ii) to pay for fees, costs and expenses in connection with the amendment and the October 2004 consent solicitation for our senior subordinated notes, and (iii) for working capital and other general corporate purposes.

The amendment retained substantially the same representations, warranties and affirmative and negative covenants as are provided in the existing senior secured credit facility, including limitations on liens, indebtedness, fundamental transactions, dispositions of assets, changes in the nature of our business, investments, acquisitions, capital and operating leases, capital expenditures, dividends, redemptions or other acquisitions of capital stock, redemptions or prepayments of other debt, transactions with affiliates, issuances of capital stock, modifications of indebtedness, organizational documents and other agreements, and retention of excess cash. The amendment also added a covenant requiring us to retain Rothschild Inc. or another financial advisor to assist with our exploration of the potential sale of some or all of the assets comprising our Pharmaceuticals Division.

The amendment also maintained the existing financial covenants under the senior secured credit facilities, including a minimum fixed charge coverage ratio, and a maximum total debt to trailing twelve-month EBITDA leverage ratio, but eliminated a minimum gross revenue covenant for the quarter ended December 31, 2004. Compliance with the fixed charge coverage ratio and the leverage ratio was also waived through the first quarter of 2005 so long as defined minimum EBITDA thresholds are satisfied. In addition, the amendment retained a covenant requiring certain levels of cash or revolver availability and increased the level of cash or revolver availability required for the period from March 31, 2005 through May 15, 2005 to $15,000,000.

The amendment also substantially retained the existing events of default under the senior secured credit facility, including, among others, nonpayment of principal, interest or fees, violations of covenants, inaccuracy of representations and warranties, a cross-default to our senior subordinated notes and other material indebtedness, bankruptcy events, and a change in control and added an event of default if we fail to pursue in good faith the exploration of the potential sale of some or all of the assets comprising our Pharmaceutical Division or other non-core assets.

58

No events of default existed under our senior credit facilities at December 31, 2004. However, since that date, events of default have occurred under our senior credit facilities that would prohibit borrowings thereunder absent a waiver from our senior lenders. These events of default included the violation of the cash/revolver availability covenant described above and the failure to timely file this Form 10-K. On March 31, 2005, we entered into a waiver agreement pursuant to which our senior lenders agreed to forbear in exercising remedies with respect to the defaults and events of default existing on that date until the earlier of April 30, 2005 or the occurrence of another default under the waiver agreement or our senior credit facilities. Upon any such forbearance termination, our senior lenders could accelerate the debt then outstanding under our senior credit facilities unless all events of default have been cured prior to such termination.

The waiver agreement also permitted us to immediately use approximately $5.7 million of our $11.3 million tax refund received in March 2005 to meet budgeted liquidity needs and required us to temporarily paydown revolving loans under the senior credit facilities with the remaining $5.6 million of the tax refund. Despite the existing events of default, the waiver permitted us to reborrow this $5.6 million, in weekly draws, to meet budgeted liquidity needs. No other borrowings are permitted under our senior credit facilities absent a consent of our senior lenders. Because of the potential for defaults under our senior credit facilities, all $175.5 million of debt outstanding at December 31, 2004 under our senior credit facilities is classified as a current liability on our consolidated balance sheet at December 31, 2004.

Subordinated Notes Due 2010

In March 2002, we issued $175 million of senior subordinated unsecured notes due 2010. The proceeds from the issuance of these notes were $173.9 million, which was net of the original issue discount. This discount will be charged to interest expense over the term of the notes. These notes originally had a fixed interest rate of 11% per annum and are guaranteed on a subordinated basis by all of our existing domestic subsidiaries and all of our future domestic subsidiaries of which we own 80% or more of the equity interests. Prior to March 28, 2005, up to 35% of the notes were redeemable with the proceeds of qualified sales of equity at 111% of par value. The terms of our senior credit facilities require us to repay all of the indebtedness under those facilities before we may repurchase any of the notes. On or after March 28, 2006, all or any portion of the notes are redeemable at declining premiums to par value, beginning at 105.5%. Under the terms of the indenture for the notes, we are required to comply with various covenants including, but not limited to, a covenant relating to incurrence of additional indebtedness.

On March 31, 2004, the lenders under our then-existing credit agreement, which was then in default, exercised their right to block us from making the interest payment to holders of our senior subordinated notes due on April 1, 2004. Accordingly, we did not make that interest payment on April 1, 2004. In addition, our failure to timely file our 2003 Form 10-K constituted a default under the indenture governing the senior subordinated notes.

On April 20, 2004, we completed a solicitation seeking the consent from holders of our senior subordinated notes to approve a refinancing or replacement of our then existing credit facilities with our current senior credit facilities and certain amendments to, and waivers under, the indenture governing the senior subordinated notes to, among other things:

59

	•	grant a lien to secure our obligations under the senior subordinated notes, which lien is junior to the liens securing our new senior credit facilities but covers the same collateral;
	•	increase the interest rate of the senior subordinated from 11% per annum to 11.5% per annum effective April 1, 2004;
	•	suspend our obligation under the indenture to file periodic reports with the SEC until the earlier of the date that our 2003 Form 10-K was filed with the SEC or September 30, 2004, and suspend our obligation under the indenture to furnish annual written statements of our accountants until the fifth day after the earlier of the date that our 2003 Form 10-K was filed with the SEC and September 30, 2004;
	•	further limit our ability to grant liens to secure certain obligations unless the liens are subordinate to the liens securing the senior subordinated notes or are otherwise permitted under the indenture; and
	•	limit our ability to incur up to $10 million of indebtedness, and to grant liens to secure that amount of indebtedness, not otherwise specifically permitted by the indenture, until our 2003 10-K was filed with the SEC or unless the indebtedness is incurred to fund an interest payment with respect to the senior subordinated debt.

Following the completion of this consent solicitation, we entered into a supplemental indenture to effect these amendments and waivers and made the interest payments that had been due on April 1, 2004, together with default interest.

On October 1, 2004, we failed to make the interest payment then due on our senior subordinated notes. The failure to make the October 1, 2004 interest payment constituted a default under our notes, subject to a 30-day cure period. On October 29, 2004, we made the interest payment, curing the default under the notes.

On October 29, 2004, we also completed a solicitation seeking the consent from the holders of our senior subordinated notes to certain amendments to, and waivers under, the indenture governing our senior subordinated notes to, among other things:

	•	permit us to incur up to $30 million of additional indebtedness under credit facilities;
	•	permit us to incur additional senior debt in order to maintain $40 million (subject to an increase up to $50 million in order to allow us to make interest payments on the senior subordinated notes) in senior debt under credit facilities in the event we are required to pay down senior debt with the proceeds of asset sales;
	•	require that debt permitted to be incurred under a fixed charge coverage ratio test set forth in the Indenture must rank on parity with or be subordinated in right of payment to the senior subordinated notes and any liens granted to secure any such parity debt shall rank pari passu with the liens securing our senior subordinated notes;
	•	require proceeds of asset sales to be used to reduce senior debt under credit facilities to $40 million;
	•	provide that the liens on assets that secure obligations under our senior subordinated notes will continue if all senior debt is repaid, but will resume as junior liens if we thereafter incur any new senior debt;
	•	prohibit the payment in cash in excess of an aggregate of $5 million to settle pending litigation, excluding payments funded or reimbursed under insurance policies, until we

60

		make the interest payments due on our senior subordinated notes on April 1, 2005 and October 1, 2005;
	•	prohibit the payment of dividends on our common stock and other restricted payments (as defined in the Indenture) until the interest payments due on our senior subordinated notes on April 1, 2005 and October 1, 2005 are paid; and
	•	temporarily increase the interest rate on our senior subordinated notes by 0.5% per annum (to 12% per annum), beginning on October 1, 2004 and ending on March 31, 2005.

The completion of the consent solicitation satisfied a condition of an amendment to our senior credit facilities (described above) that, among other matters, made available a supplemental term loan under the senior credit facilities that was used in part to make the October 1, 2004 interest payment on our senior subordinated notes, together with default interest thereon, on October 29, 2004 and to pay the consent fee described below. The October 29, 2004 interest payment cured the existing default under the senior subordinated notes.

In connection with the October 2004 consent solicitation, we paid a consent fee to the holders of senior subordinated notes who had submitted valid and unrevoked consents by the expiration date of the consent solicitation of $20 for each $1,000 in principal amount of senior subordinated notes for which a consent was submitted. Following discussions with representatives of an ad hoc committee of holders of the senior subordinated notes, we offered to pay the same consent fee with respect to senior subordinated notes for which a valid and unrevoked consent had not been properly submitted by the expiration of the consent solicitation, if the holder of such senior subordinated notes completed a consent and release for payment by February 7, 2005 that consented to the proposed amendments and waivers described above and waived all claims it may have against us, the trustee under the indenture governing the senior subordinated notes, the payment agent in the consent solicitation, and our and their respective directors, officers, employees, agents, attorneys, affiliates and advisors with respect to matters related to the consent solicitation. On February 9, 2005, we paid approximately $1.0 million in additional consent fees pursuant to properly submitted consents and releases for payment.

At December 31, 2004, we were not in default under the covenants under the senior subordinated notes. Our failure to timely file this Annual Report on Form 10-K for the fiscal year ended December 31, 2004 (accompanied by a certificate of our independent accountants) constituted a default under the notes on March 17, 2005. In addition, we have not paid the $10.5 million of scheduled interest due on April 1, 2005 on our notes. An event of default will occur under the indenture governing the notes if the interest payment is not made within 30 days after April 1. Such an event of default would entitle the trustee under the indenture for the notes or the holders of 25% of the principal amount of the notes to accelerate the notes. Any event of default entitling the trustee or the holders of the notes to accelerate the notes would also constitute an event of default under our senior credit facilities entitling our senior lenders to accelerate the debt thereunder.

Because of the potential for defaults under our notes at December 31, 2004, all $175.0 million of debt outstanding at December 31, 2004 under our notes is classified as a current liability on our consolidated balance sheet at December 31, 2004.

61

Interest Rate Hedging Agreement

Concurrently with the issuance of our senior subordinated notes, we entered into an interest rate hedging agreement to effectively convert interest expense on a portion of the senior subordinated notes for the term of the notes from an 11% fixed annual rate to a floating annual rate equal to 6-month LIBOR plus a base rate. In 2003, we sold the then outstanding hedging agreement, and replaced it with a similar interest rate hedging agreement. The amounts we received, less the termination payment and the interest benefits earned through the dates of sale, have been recorded as premiums to the carrying amount of the notes and are being amortized into interest income over their remaining life.

Our obligations under the interest rate hedging agreement were secured by collateral under our then-existing senior credit facilities.

As a condition to establishing our new senior credit facilities, we terminated the interest rate hedging agreement in April 2004. Our termination obligations under the interest rate hedging agreement were approximately $9.4 million, which amount was paid upon termination of that agreement.

Income Tax Refunds

Income tax refund proceeds are serving as a source of near term liquidity. In March 2005, we received a tax refund of approximately $11.3 million, all or substantially all of which was required to be paid down under our senior credit facilities. On March 31, 2005, we entered into a waiver agreement pursuant to which our senior lenders permitted us to immediately use approximately $5.7 million of the tax refund to meet budgeted liquidity needs and required us to temporarily paydown revolving loans under the senior credit facilities with the remaining $5.6 million of the tax refund. Despite existing events of default under our senior credit facilities, the waiver permitted us to reborrow this $5.6 million, in weekly draws, to meet budgeted liquidity needs.

Commitments and Contingencies

We may have to make contingent payments of $4.7 million over three years in connection with the purchase of our Charleston, South Carolina manufacturing facility, based on the level of manufacturing revenues at this facility. At December 31, 2004 these contingent payment obligations are not liabilities and have not been recorded on our consolidated balance sheet.

We made interest payments on the senior subordinated notes of $9.7 million in April 2004 and $10.2 million in October 2004. An interest payment of $10.5 million was due on our senior subordinated notes on April 1, 2005 and was not paid. An additional $10.1 million interest payment is due on such notes on October 1, 2005.

We are a party to several significant lawsuits and are being investigated by the SEC and the U.S. Attorney’s Office for the Western District of North Carolina. Any damages or litigation costs (including any indemnification of, or payment of litigation expenses for, our current and former officers, directors and employees who have been named as defendants in these lawsuits or are subject to these investigations) that are not covered by applicable insurance policies that we

62

have, including our D&O policy, and thus are ultimately borne by us as a result of an adverse determination in these lawsuits, are significant contingent liabilities that are not recorded as liabilities on our balance sheet but could result in significant cash payment obligations in the future. In addition, the U.S. Attorney’s Office, SEC and other government agencies that are investigating or might commence an investigation of aaiPharma could impose, based on a claim of fraud, material misstatements, violation of false claims law or otherwise, civil and/or criminal sanctions, including fines, penalties, and/or administrative remedies. The potential for government sanctions also represents a significant contingent liability that is not recorded as a liability on our balance sheet but could result in significant cash payment obligations in the future. We expect to incur significant legal and related costs and expenses in connection with these lawsuits and investigations in 2005. For more information on these lawsuits and investigations, see Note 13 of Notes to Consolidated Financial Statements included elsewhere in this report.

The following schedule summarizes contractual obligations and commitments at December 31, 2004 (in thousands):

The scheduled maturity for our senior credit facilities is April 21, 2007 and the scheduled maturity for our senior subordinated notes is April 1, 2010. However, due to the potential for defaults under our senior credit facilities and notes, the debt outstanding thereunder is classified as a current liability on our consolidated balance sheet at December 31, 2004. Our purchase commitments are primarily related to outstanding orders and commitments with suppliers to purchase finished goods related to our pharmaceutical products. In the fourth quarter of 2004, we recorded a charge of $11.7 million, and established a corresponding reserve, related to a pharmaceutical product manufacturing supply agreement entered into in 2003 requiring us, subject to the terms and conditions of the agreement, to purchase a minimum level of products on a take-or-pay basis by September 2006. We do not expect to be able to fulfill our purchase obligations under this agreement during this period. This purchase commitment is reflected in the table above. We are negotiating with the manufacturer under this agreement to extend the term of our obligation to purchase the minimum level of products by an additional multi-year period and to include additional products to be manufactured for us under this agreement and applied against our minimum purchase requirement. If we are successful in amending the agreement on this basis, the reserve and corresponding charge may be reversed in a subsequent period. We cannot provide any assurance, however, that we will be successful in amending the agreement on these, or any other, terms.

63

Our liquidity needs increased during 2004, and our annual net interest expense may exceed $46 million in 2005. We failed to make an interest payment on our senior subordinated notes of $10.5 million due on April 1, 2005, and we have another interest payment on such notes of approximately $10.1 million due on October 1, 2005.

We will incur substantial cash expenses in 2005, resulting from the cost of advisors, such as legal counsel (including legal counsel to the ad hoc committee of holders of our senior subordinated notes and legal counsel for our senior lenders), FTI Palladium Partners, the ad hoc committee’s financial advisor, our senior lenders’ financial advisor, and our financial advisor in connection with potential asset sales. In addition, we will continue to incur significant severance and restructuring costs in connection with the restructuring plans implemented in 2004.

On March 31, 2004, each of Moody’s Investors Service and Standard & Poor’s Ratings Services announced that it had lowered our corporate credit rating: Moody’s to Caa2 from B2 and Standard & Poor’s to CCC from B+. At the same time, Moody’s lowered its rating of our senior subordinated notes to Ca from Caa1 and our senior unsecured issuer rating to Caa3 from B3. Standard & Poor’s lowered its senior secured debt rating to CCC+ from BB-, and its subordinated debt rating to CC from B-. On December 31, 2004, Moody’s confirmed the Caa2 corporate credit rating, lowered its rating of our senior subordinated notes to C from Ca and our senior unsecured issuer rating to Ca from Caa3. On March 17, 2005, Standard & Poor’s Ratings Services announced that it had lowered our corporate credit rating from CCC to CC and our subordinated debt rating from CC to C, and on April 4, 2005, it lowered both ratings to D, the lowest rating possible, following our failure to pay the $10.5 million interest payment due on April 1, 2005, on our senior subordinated notes. These actions may negatively affect our ability to raise any necessary capital through issuances of debt securities or other debt instruments on acceptable terms, or at all.

Analysis of Liquidity

We incurred a substantial net loss and loss from operations for 2004 and the quarter ended December 31, 2004. As a result of our recurring substantial operating losses, we did not have available sufficient cash on hand, or the ability to borrow under our senior credit facilities, to pay the approximately $10.5 million of scheduled interest due on April 1, 2005 on our $175 million of senior subordinated notes due 2010.

In March 2005, we received a tax refund of approximately $11.3 million, all or substantially all of which was required to be paid down under our senior credit facilities. Events of default had also occurred under our senior credit facilities that would prohibit borrowings thereunder absent a waiver from our senior lenders. On March 31, 2005, we entered into a waiver agreement pursuant to which our senior lenders agreed to forbear in exercising remedies with respect to these existing events of default until the earlier of April 30, 2005 or the occurrence of another default under the waiver agreement or our senior credit facilities. Upon any such forbearance termination, our senior lenders could accelerate the debt then outstanding under our senior credit facilities unless all events of default have been cured. This waiver agreement also permitted us to immediately use approximately $5.7 million of the tax refund to meet budgeted liquidity needs and required us to temporarily paydown revolving loans under the senior credit facilities with the remaining $5.6 million of the tax refund. Despite the existing events of default, the waiver

64

permitted us to reborrow this $5.6 million, in weekly draws, to meet budgeted liquidity needs. These tax refund proceeds and borrowings have permitted us to meet near term liquidity needs.

However, no other borrowings are permitted under our senior credit facilities absent a consent of our senior lenders. Our failure to make the $10.5 million interest payment due on our senior subordinated notes on April 1, 2005 will also be an event of default under the indenture governing such notes if the interest payment is not made within 30 days after April 1. Such an event of default would permit the acceleration of the notes.

We have been exploring a potential sale of some or all of the assets of our Pharmaceuticals Division, as well as other operating assets. In October 2004, we engaged Rothschild Inc. to assist us, and in November 2004 Rothschild began a process to gauge the interest in any asset sale transaction by contacting potential strategic and financial purchasers. Potential purchasers expressing an interest were provided an opportunity to examine detailed information regarding our Pharmaceuticals Division, its business, products and products in development. On March 31, 2005, we entered into a limited exclusivity agreement with a potential purchaser of certain of the assets of our Pharmaceuticals Division to facilitate continued due diligence and negotiation over a potential sale. This written exclusivity agreement expired by its terms on April 22, 2005, though we are continuing to negotiate with this potential purchaser on an exclusive basis. We have not reached a definitive agreement with this potential purchaser regarding a sale and we cannot provide any assurance that any material asset sale will be agreed upon or completed. In addition, we have not determined to sell any material assets, and we plan to continue to operate our Pharmaceuticals Division if we do not complete such a sale of its assets.

Pursuant to the terms of our senior credit facilities, the net proceeds of any material asset sale are required to be applied to permanently reduce our outstanding indebtedness under our senior credit facilities. Similarly, the indenture governing our notes requires that the net proceeds of material asset sales be applied to permanently reduce indebtedness under the senior credit facilities to $40 million, at which point we would be permitted under the indenture to incur an additional $10 million of indebtedness solely to fund payments of interest on the notes. Accordingly, such a sale would not provide liquidity unless the amount of the net proceeds was in excess of the amount needed to discharge our indebtedness under the senior credit facilities or our senior lenders and holders of our notes consented to permit a portion of the net proceeds to be used for a purpose other than repayment of our senior debt. Based on our exploration of a possible sale of some or all of the assets of our Pharmaceuticals Division, we believe that, the sale of all of the assets of our Pharmaceuticals Division at this time, given our financial condition and other circumstances, may not yield net proceeds in excess of the amount needed to discharge the indebtedness under our senior credit facilities. A sale of some or all of the assets of the Pharmaceutical Division would require the consent of the Lenders under our senior credit facilities, and such a sale may require the consent of the holders of our notes and our stockholders.

In light of our current financial condition, we believe that our operations can no longer support our existing debt and that we must restructure our debt to levels that are more in line with our operations. Thus, it is highly likely that we will seek relief under chapter 11 of the U.S. Bankruptcy Code which would substantially dilute and may eliminate the interests of the holders of our common stock.

65

We have continued our engagement of FTI as our financial advisor to assist us in exploring our alternatives. With FTI, we have held discussions with Lenders under our senior credit facilities and advisors to an ad hoc committee of holders of our notes in an effort to negotiate a consensual restructuring of our debt. In addition, we have engaged in discussions and negotiations with prospective lenders to obtain financing sufficient to refinance indebtedness outstanding under the senior credit facilities and/or to provide additional credit facilities in order to fund our operations while in a chapter 11 proceeding under the Bankruptcy Code if we were to commence such a proceeding.

Our independent registered public accountants have advised our management and the Audit Committee of our Board of Directors that our recurring losses from operations raise substantial doubt regarding our ability to continue to operate as a going concern. Therefore, our independent registered public accountants have included in their report on our consolidated financial statements an explanatory paragraph addressing the substantial doubt regarding our ability to continue to operate as a going concern.

Critical Accounting Policies

Our management has concluded that our internal control over financial reporting is not effective due to the existence of several material weaknesses. Several of these material weaknesses relate to the critical accounting policies discussed below and further complicate the judgments necessary in those accounting areas. Our management’s report on internal control over financial reporting is included with the financial statements reflected in Item 8 of this Annual Report on Form 10-K.

Revenue Recognition

We recognize revenue in accordance with the Securities and Exchange Commission’s Staff Accounting Bulletin No. 101, “Revenue Recognition in Financial Statements” as amended by Staff Accounting Bulletin No. 104 (together, “SAB 101”) and Statement of Financial Accounting Standards No. 48 “Revenue Recognition When Right of Return Exists” (“FAS 48”). SAB 101 states that revenue should not be recognized until it is realized or realizable and earned. Revenue is realized or realizable and earned when all of the following criteria are met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services have been rendered; (3) the seller’s price to the buyer is fixed and determinable; and (4) collectibility is reasonably assured. FAS 48 states that revenue from sales transactions where the buyer has the right to return the product shall be recognized at the time of sale only if (1) the seller’s price to the buyer is substantially fixed or determinable at the date of sale, (2) the buyer has paid the seller, or the buyer is obligated to pay the seller and the obligation is not contingent on resale of the product, (3) the buyer’s obligation to the seller would not be changed in the event of theft or physical destruction or damage of the product, (4) the buyer acquiring the product for resale has economic substance apart from that provided by the seller, (5) the seller does not have significant obligations for future performance to directly bring about resale of the product by the buyer, and (6) the amount of future returns can be reasonably estimated.

66

Net Revenues. Our consolidated net revenues represent our total revenues less allowances for customer credits, including estimated discounts, rebates, chargebacks, product returns and non research and development expenses reimbursed by customers. As is customary in the pharmaceutical industry, we accept returns of products we have sold as the products near their expiration date. At the time we recognize revenue from product sales, we record an adjustment, or decrease, to revenue for estimated chargebacks, rebates, discounts and returns.

The following table sets forth our consolidated gross revenues and the amount of dilution to consolidated revenues resulting from allowances for customer credits, including discounts, rebates, chargebacks, product returns and other allowances for each of 2004, 2003 and 2002:

Allowances for customer credits as a percentage of consolidated gross revenues were 21.2% for 2004 as compared to 30.2% for 2003. This change is primarily related to lower pharmaceutical returns and chargeback reserve needs based on changes in sales mix, primarily due to lower Brethine sales and the sale of our MVI product line.

Net revenues are reported for our three operating segments in 2004, which were product sales, development services and product development.

Product Sales. We recognize revenues for product sales at the time title and risk of loss are transferred to the customer, and the other criteria of SAB 101 and FAS 48 are satisfied, which is generally at the time products are received by our customers. Product shipping and handling costs are included in cost of sales. We accept returns of products near their expiration date.

At the time we recognize revenue from product sales, we record an adjustment, or decrease, to revenue for estimated chargebacks, rebates, discounts and returns. Revenue reserves are established on a product-by-product basis. These revenue reductions are established by management as its best estimate at the time of sale based on each product’s historical experience adjusted to reflect known changes in the factors that impact such reserves. Reserves for chargebacks, rebates and discounts are established based on the contractual terms with our customers; analysis of historical levels of discounts, chargebacks and rebates; communications with customers and purchased information about the rate of prescriptions being written and the levels of inventory remaining in the distribution channel, as well as our expectations about the market for each product and anticipated introduction of competitive products. The reserves for chargebacks and returns are the most significant estimates used in the recognition of our revenue from product sales. We have established contract prices for certain indirect customers that are supplied by our wholesale customers. A chargeback represents the difference between the current published wholesale acquisition cost and the indirect customers’ contract prices.

67

Prior to 2003, the amount of actual product returns experienced by the Company had not been significant. As a result, actual returns were charged against revenue in the period they occurred and aggregate revenue reserves were evaluated to determine if they were sufficient to cover estimated chargebacks, rebates and related allowances, as well as the expected rate of returns, and adjusted as deemed necessary. In 2003, we began segregating our products return reserve, which prior thereto we believed was adequately covered by our aggregate revenue reserves for chargebacks, rebates and related allowances. We increased the level of detail included in our analyses to include analyzing inventory in the channel to determine remaining shelf life. Our returns reserve needs are primarily related to the number of months of inventory estimated to be in the distribution channel. Levels of inventory in the distribution channel are monitored and estimated based on information we purchase from the wholesalers, combined with active discussions between our sales personnel and the wholesalers we supply. In addition, our actual sales, returns and chargeback history are used to assess the reasonableness of the estimated number of months of inventory on hand at our wholesalers. The shelf life of products remaining in the distribution channel is estimated based on an analysis of the lots sold. Each batch has a specific expiration date. A review of the actual returns history is performed and the run rate of sales out of the distribution channel is estimated. Estimated product returns reserves are adjusted based on these reviews. Reserves may also be adjusted to reflect any significant changes in trends or based upon new information that we believe may affect the reserve needs. Allowances for new product introductions are estimated based on our experiences for similar products that we currently market and are adjusted as deemed necessary based on our experience with each product. Our reserve analysis also includes a review for the potential introduction of generic competition and the resulting impact on pricing and returns reserves. Existing reserves may be adjusted accordingly to reflect our estimate for any impact these factors may have. We continually monitor our assumptions with respect to our revenue reserves for product sales and modify them if necessary.

Revenues from new product launches and the sale of Brethine to a specialty wholesaler have been recorded under the consignment model. Under the consignment model, we do not recognize revenue upon receipt of product by wholesalers, but instead invoice the wholesaler, record deferred revenue at gross invoice sales price and classify the inventory held by the wholesaler as consignment inventory at our cost of such inventory. We recognize revenue when such inventory is sold through to the wholesalers’ customers, on a first-in first-out (FIFO) basis.

Product Development. Product development revenues consist of royalty revenues and licensing fees. We recognize royalty revenues as earned based on sales of the underlying products. Each of our licensing agreements is reviewed to determine the appropriate revenue recognition treatment under SAB 101. Revenues from upfront licensing fees are deferred and amortized over the term of the associated agreement or as ongoing services are performed. Revenues resulting from achieving certain milestones stipulated in our agreements are recognized when the specific milestone is achieved. Milestones are based upon the occurrence of a substantive element specified in the contract or as a measure of substantive progress towards completion under the contract.

Development Services. We recognize the majority of our development services revenues from fee-for-service contracts on a proportional performance basis as the work is performed. This is based on the ratio of actual direct costs incurred to total estimated direct contract costs, which is

68

the best indicator of performance of these contract obligations. This ratio is multiplied by the estimated contract value to determine the revenue to be recognized. The proportional performance method requires us to estimate total expected revenue, costs and profitability of the contract. These estimates are reviewed periodically and, if these estimates change or actual results differ from expected results, an adjustment is recorded in the period in which they become reasonably estimable. These adjustments could have a material effect on our results of operations. Historically, there have not been significant variations between contract estimates and actual costs incurred which were not recoverable from clients. Changes in the scope of work generally result in an amendment to contract pricing terms. Amended contract amounts are not included in net revenues until earned and realization is assured. We also recognize revenue on a time and materials basis in accordance with the specific contract terms. Revenues recognized prior to contract billing terms are recorded as work in progress. Provisions for losses on contracts, if any, are recognized when identified. Clients generally may terminate services at any time, however the majority of our contracts contain provisions that require payment for all services rendered to date, even those services that have not yet been billed. We perform ongoing credit evaluations of our customers and maintain reserves for potential uncollectible accounts.

Intangible Assets

When we acquire the rights to manufacture and sell a product, we record the aggregate purchase price, along with the value of the product related liabilities we assume, as intangible assets. We use the assistance of valuation consultants to help us allocate the purchase price to the fair value of the various intangible assets we have acquired. Then, we must estimate the economic useful life of each of these intangible assets in order to amortize their cost as an expense in our statement of operations over the estimated economic useful life of the related asset. The factors that drive the actual economic useful life of a pharmaceutical product are inherently uncertain, and include physician loyalty and prescribing patterns, competition by products prescribed for similar indications, future introductions of competing products not yet FDA approved, the impact of promotional efforts and many other issues. We use all of these factors in initially estimating the economic useful lives of our products, and we also continuously monitor these factors for indications of appropriate revisions.

In assessing the recoverability of our intangible assets, we must make assumptions regarding estimated undiscounted future cash flows and other factors. If the estimated undiscounted future cash flows do not exceed the carrying value of the intangible assets we must determine the fair value of the intangible assets. If the fair value of the intangible assets is less than its carrying value, an impairment loss will be recognized in an amount equal to the difference. If these estimates or their related assumptions change in the future, we may be required to record impairment changes for these assets. In addition, material adjustments to our forecasted revenues from the sales of any of our acquired product lines including Brethine and Darvocet may require us to employ different assumptions with respect to our estimated cash flows. We review intangible assets for impairment at least annually and whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If we determine that an intangible asset is impaired, a non-cash impairment charge would be recognized.

69

For the year ended December 31, 2001, goodwill, defined as the excess of the purchase price over the fair value of the net assets of acquired businesses, was amortized over 20 years. In accordance with SFAS 141, we ceased amortization of goodwill as of January 1, 2002. For purchase business combinations consummated subsequent to June 30, 2001, goodwill and indefinite-lived intangible assets are not amortized, but are evaluated for impairment on an annual basis or as impairment indicators are identified. Other identifiable intangible assets are amortized, if applicable, on a straight line basis over their estimated useful lives, which range from 3 to 20 years.

Our goodwill and intangible assets consist of the following:

On a periodic basis, or as otherwise required, we assess the value of our goodwill, intangibles and other assets by determining their ability to recover the unamortized balances over the remaining useful lives. Goodwill, intangibles and other long lived assets determined to be unrecoverable are written off in the period in which such determination is made.

Set forth in the table below are the details of the purchase price allocations for of all our major product line acquisitions since the beginning of 2001. The table lists the assets, the value allocated to each asset, how the value was determined, and the useful life assigned to each asset. In these acquisitions, the only tangible assets acquired were inventory and marketing/promotional materials, which were valued based on internal analyses and data provided by the sellers. Inventory obtained at time of acquisition was valued at the estimated selling price less the cost of disposal and a reasonable selling profit. Marketing/promotional materials received were generally outdated and in limited quantities, so no material value was assigned to them in the purchase price allocations. We engaged third-party valuation consultants to assist in purchase price allocations, including identification of intangible assets, recommendations of fair value of intangible assets, and determination of expected lives of those assets. Intangible assets that arose from contractual or legal rights and other intangible assets that were separable, as provided in paragraph 39 of SFAS 141, were identified. Among the assets that were considered for recognition were trademarks, Internet domain names, non-competition agreements, customer lists, backlogs, customer contracts and non-contractual relationships, licensing and royalty agreements, supply contracts, employment contracts, patented and unpatented technology, and trade secrets.

70

The third-party valuation consultants reviewed pertinent facts and recommended for each asset the appropriate generally accepted valuation approach and methodology from among the cost, market, and income approaches. Where possible, a valuation derived using an alternative valuation approach or methodology was presented and used by management to evaluate the reasonableness of the recommended fair value.

We recorded an $87.1 million charge in December 2004 due to the impairment of intangible assets associated with our Darvon/Darvocet products. In 2003 and 2004, we recorded charges of $15.9 million and $6.4 million, respectively, due to the impairment of an intangible asset associated with our Brethine product. These impairments are not reflected in the following table.

71

72

Inventories

Our inventories are valued at the lower of cost (determined on a first-in, first-out basis) or market. We review our inventory for short-dated or slow-moving product and inventory commitments under supply agreements based on projections of future demand and market conditions. For inventory so identified, we estimate market value or net sales value based on current realization trends. If the projected net realizable value is less than cost, on a product basis, we provide a reserve to reflect the lower value of that inventory. We recognize inventory losses at the time such losses are evident rather than at the time products are actually sold. We also maintain supply agreements with some of our vendors which contain minimum purchase requirements. We estimate future inventory requirements based on current trends. If our estimated future inventory requirements exceed estimated shipments to our customers, we record a charge in direct costs. If we over- or under-estimate the amount of inventory that will not be sold prior to expiration, there may be a material adverse impact on our consolidated financial condition and results of operations.

Income Taxes

Income taxes are accounted for under the liability method. This approach requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of differences between the tax basis of assets or liabilities and their carrying amounts in the consolidated financial statements. A valuation allowance is provided for deferred tax assets if it is more likely than not that these items will either expire before we are able to realize their benefit or if future deductibility is uncertain. Developing the provision for income taxes requires significant judgment and expertise in federal and state income tax laws, regulations and strategies, including the determination of deferred tax assets and liabilities and, if necessary, any valuation allowances that may be required for deferred tax assets. Our judgments and tax strategies are subject to audit by various taxing authorities. While we believe we have provided adequately for our income tax liabilities in our consolidated financial statements, adverse determinations by these taxing authorities could have a material adverse effect on our consolidated financial condition and results of operations.

Research and Development Arrangements

Research and development expense was 8% of our consolidated net revenues in 2004. However, due to liquidity constraints, we do not believe we will be able to fund additional research and development activities in 2005 at this level, and we may not be able to fund additional research and development activities at all. The only product under active development is the Darvocet line extension. The following product development table identifies, for each of our major development programs in 2004, the stage of development at December 31, 2004 of the lead product or products in each program, research and development spending on each program in

73

2004, cumulative research and development spending on each program from inception through December 31, 2004, an estimate of the additional research and development expense to complete the development of the lead product in the program, and the year in which we anticipate completing the lead product in the program. The estimated additional expense to complete the lead product and the timing of completion represent our estimates. As we continue to evaluate our liquidity position and the viability of these development programs, including an evaluation of our interim results and other information, we may decide to cease research and development activities on some or all of these products, or to change the scope and direction of a program as well as how we allocate our research and development spending. In addition, our actual costs in developing these products may be materially different from our estimates due to uncertainties inherent in product development. Moreover, even if we are able to fund additional research and development of these products, we may not be able to successfully develop, commercialize or license the products or technologies included in the table.

74

and development activities in 2005 at the same level as 2004, and we may not be able to fund additional research and development activities at all. The only product under active development is the Darvocet line extension. Thus, we are unable to estimate actual completion dates for these products, or whether we will be able to complete these programs at all, due to our liquidity position.

In addition to the specifically identified programs named in the table, we have targeted additional product development programs or projects. These other programs or projects may require significant research and development spending in future periods. However, due to liquidity constraints, we do not believe we will be able to fund additional research and development activities in 2005 at the same level as 2004, and we may not be able to fund additional research and development activities at all.

There is a risk that any specific research and development program or project may not produce revenues. We believe that the potential profit margins from successful development programs or projects will compensate for costs incurred for unsuccessful projects. See “—Risk Factors and Forward-Looking Statements.”

Related Party Transactions

For a description of our related party transactions, see Note 10 to our Consolidated Financial Statements included elsewhere in this report.

Inflation

We believe that the effects of inflation generally do not have a material adverse effect on our consolidated results of operations or financial condition.

New Accounting Standards

In December 2004, the Financial Accounting Standards Board issued Statement of Financial Accounting Standards No. 123 (revised 2004), “Share-Based Payment”, (SFAS No. 123(R)), which amends SFAS No. 123, “Accounting for Stock-Based Compensation”, and supersedes APB Opinion No. 25, “Accounting for Stock Issued to Employees.” SFAS No. 123(R) requires compensation expense to be recognized for all share-based payments made to employees based on the fair value of the award at the date of grant, eliminating the intrinsic value alternative allowed by SFAS No. 123. Statement 123(R) requires all share-based payments to employees, including grants of employee stock options, to be recognized in the financial statements based on their fair values (i.e., pro forma disclosure is no longer an alternative to financial statement recognition). SFAS No. 123(R) must be adopted in the first annual period beginning after June 15, 2005.

We currently plan to adopt SFAS No. 123(R) on January 1, 2006. This change in accounting is not expected to materially impact our financial position. However, because we currently account for share-based payments to our employees under APB No. 25, our results of operations have not included the recognition of compensation expense for the issuance of stock option awards. Had we applied the fair-value criteria established by SFAS No. 123(R) to previous stock option grants, the impact to our results of operations would have approximated the impact of applying

75

SFAS No. 123, which was a reduction to net income of approximately $6.0 million in 2004, $9.7 million in 2003 and $6.5 million in 2002.

We do not believe that any other recently issued, but not yet effective, accounting standards will have a material impact on the company

Risk Factors and Forward Looking Statements

Forward-Looking Statements and “Safe Harbor” Language

This report contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Words such as “estimate,” “project,” “intend,” “anticipate,” “believe” and similar expressions are intended to identify forward-looking statements. The forward-looking statements contained in this report include statements about future financial and operating results, including the anticipated financial condition, results of operations, business strategies, operating efficiencies, competitive positions, growth opportunities for existing products and businesses, and markets for our common stock. Forward-looking statements also include statements about potential events of default, or acceleration of the debt, under our senior credit facilities and the notes, proposed financial restructuring transactions, the need to seek protection under the Bankruptcy Code, potential asset sales, our internal control over financial reporting, and plans and objectives of our management. These statements are based on the current expectations and beliefs of our management and are subject to a number of factors and uncertainties, including the matters noted above, that could cause actual outcomes to differ materially from those described in the forward-looking statements. These statements are not guarantees of future outcomes, involve certain risks, uncertainties and assumptions that are difficult to predict, and are based upon assumptions as to future events that may not prove accurate. Therefore, actual outcomes may differ materially from what is expressed in the forward-looking statement. Additional risks and uncertainties pertaining to the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements:

	•	our ability to obtain an agreement with our senior lenders and an ad hoc committee of holders of our notes to a plan to restructure our debt and to effect such an agreement,
	•	our ability to comply with, or receive further or continued waivers, consents or forbearances of our lenders with respect to, financial covenants under our senior credit agreement or other indebtedness or receive waivers of any defaults under such agreements,
	•	our ability to generate sufficient cash from operations, asset sales and other transactions to fund our cash needs, and our inability to do so has resulted in our plan to file a voluntary petition for bankruptcy,
	•	our ability to continue to operate in the ordinary course and to manage our relationships with our lenders, bondholders, customers, vendors and suppliers and employees,

76

	•	our ability to attract, retain and complete product development projects and other customer relationships,
	•	our ability to obtain critical supplies,
	•	our ability to effect the sale of some or all of the assets comprising our Pharmaceuticals Division and other assets, if we choose to do so, on attractive terms or at all and to obtain necessary consents and waivers from our Lenders and the holders of the notes to permit such sales and the application of the net proceeds of such sales for working capital purposes,
	•	our ability to obtain additional credit facilities in order to fund our operations while in a chapter 11 proceeding under the U.S. Bankruptcy Code if we were to commence such a proceeding,
	•	the impact of material weaknesses in internal control over financial reporting on our ability to timely prepare accurate financial statements and to avoid material adverse effects on our financial and operational results,
	•	our ability to timely remediate identified material weaknesses in internal control over financial reporting,
	•	the investigations by the U.S. Attorney’s office and the SEC into our financial reporting and related activity,
	•	the outcome of pending litigation filed against us,
	•	the outcome of pending litigations we have filed against others,
	•	significant changes in our management team and the loss of critical personnel,
	•	our ability to attract critical personnel,
	•	demand for our products and services and the products we produce for others,
	•	the prices that we or our customers can obtain for our products and services,
	•	the level of competition we face,
	•	distributors’ and wholesalers’ inventory levels and ordering and payment patterns,
	•	the amounts and timing of product returns and chargebacks,
	•	timely success in product development and regulatory approvals for new products and line extensions, both for our proprietary products and products we develop for our customers,
	•	market acceptance of new products and line extensions at levels that justify our cost of developing or acquiring these products,

77

	•	actions by the United States Food and Drug Administration (“FDA”) in connection with submissions related to our products or those of our competitors or customers,
	•	other governmental regulations and actions affecting our products and services or those of our competitors,
	•	third-party payer decisions and actions affecting our products or those of our competitors or customers,
	•	our ability to participate in federal health care programs, including the Medicare and Medicaid programs,
	•	developments in patent or other proprietary rights owned by us or others, and
	•	general conditions in the economy and capital markets.

Some of these factors and additional factors that may cause our actual results to differ materially are discussed below. Whenever you read or hear any subsequent written or oral forward-looking statements attributable to us or any person acting on our behalf, you should keep in mind the cautionary statements contained or referred to in this report.

We do not undertake, and expressly disclaim, any obligation to update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

Risk Factors

The risks and uncertainties described below are intended to highlight risks and uncertainties that are specific to us but are not the only risks and uncertainties that we face. Additional risks and uncertainties, including those generally affecting the industry in which we operate and risks and uncertainties that we currently deem immaterial, also may impair our business and the value of any investment in us.

Risks Relating to a Potential Bankruptcy Proceeding and Our Financial Condition

It is highly likely that we will seek relief under chapter 11 of the U.S. Bankruptcy Code which would substantially dilute and may eliminate the interests of the holders of our common stock.

In light of our current financial condition, we believe that our operations can no longer support our existing debt and that we must restructure our debt to levels that are more in line with our operations. Moreover, we do not have a source of liquidity to fund near term operations and believe that we will be able to secure necessary liquidity sources only in the context of a Chapter 11 bankruptcy proceeding. Accordingly, it is highly likely that we will seek relief under chapter 11 of the Bankruptcy Code which would substantially dilute and may eliminate the interests of the holders of our common stock.

We reported a consolidated net loss of $191.2 million and $32.7 million for the years ended December 31, 2004 and 2003, respectively. As a result of our substantial and recurring operating

78

losses, we do not have adequate sources of liquidity to fund our operations in the near term. Events of default have occurred under our senior credit facilities that would permit the lenders to accelerate the debt thereunder absent a forbearance or waiver. While we have obtained a temporary forbearance with respect to such events of default, such forbearance will expire no later than April 30, 2005 absent a further consent from our senior lenders. In addition, we did not pay the $10.5 million interest payment due on April 1, 2005 under our senior subordinated notes. The failure to pay such interest payment within 30 days after April 1 would constitute an event of default under such notes, permitting acceleration thereunder.

We received an $11.3 million tax refund in March 2005 and a waiver agreement from our senior lenders that permitted immediate use of approximately $5.7 million of such tax proceeds for liquidity purposes and required the remaining $5.6 million to pay down revolving loans under our senior credit facilities. While this $5.6 million can be reborrowed to meet budget working capital expenses under the terms of this waiver agreement, no additional loans are available under our senior credit facilities absent consent from our senior lenders. We have reborrowed the entire $5.6 million.

We have been exploring a potential sale of some or all of the assets of our Pharmaceuticals Division, as well as other operating assets, for liquidity purposes. We executed an exclusivity agreement with a potential purchaser of certain of the assets of our Pharmaceuticals Division. This written agreement expired on April 22, 2005, though we are continuing to negotiate with this potential purchaser on an exclusive basis. We have not reached a definitive agreement with this potential purchaser and cannot provide any assurance that any material asset sale will be agreed upon or completed. If we are able to reach a definitive agreement with this potential purchaser, it is highly likely that the sale would be completed as part of a bankruptcy proceeding because the potential purchaser is seeking to require that any such sale be completed as part of a bankruptcy proceeding. In addition, even if such sale were not part of a bankruptcy proceeding, substantially all of the proceeds of any material asset sale are required under our debt documents to be used to pay down senior debt and we would need consents of our senior lenders and noteholders to waive this requirement. We would also require the consent of our senior lenders, and may require the consent of our stockholders and noteholders, to approve the consummation of any asset sale not completed as part of a bankruptcy proceeding.

In the event of a bankruptcy proceeding, we may be unable to secure debtor-in-possession financing necessary to fund our continued operation.

We have engaged in discussions and negotiations with prospective lenders to obtain financing sufficient to refinance indebtedness outstanding under our senior credit facilities and/or to provide additional credit facilities in order to fund our operations while in a chapter 11 proceeding under the Bankruptcy Code (“DIP Financing”) if we were to commence such a proceeding. If we are able to obtain DIP Financing, any DIP Financing will be subject to approval by the bankruptcy court in any bankruptcy proceeding and we may be unable to obtain that approval. If we are unable to secure adequate debtor-in-possession financing in a bankruptcy proceeding, we will be unable to fund the continued operations of our company. We believe the failure to continue to operate our company as a going concern would substantially reduce the value of our enterprise.

79

If we seek relief under chapter 11 of the Bankruptcy Code we may be unable to develop a plan of reorganization acceptable to our creditors and may be required to liquidate our assets and cease to operate as a going concern.

If we seek relief under chapter 11 of the Bankruptcy Code, we do not anticipate that at the time we file for relief we will have a plan of reorganization or any understanding with our creditors with respect to a plan of reorganization. Our future results are dependent upon our developing, confirming and implementing, on a timely basis, a plan of reorganization. Moreover, we may be unable to develop, confirm and implement a plan of reorganization in bankruptcy proceedings. If we cannot develop, confirm and implement a plan of reorganization, we may be required to liquidate our assets and cease to operate as a going concern.

In a bankruptcy proceeding, we may be unable to operate under the terms of the DIP Financing which may preclude our access to a source of liquidity necessary to fund the continued operation of our business.

If we seek relief under chapter 11 of the Bankruptcy Code and secure DIP Financing, we may be unable to operate under the terms of the DIP Financing or may otherwise violate the terms of the DIP Financing. Based on our preliminary discussions with lenders, the definitive agreements establishing any DIP Financing that we are able to obtain may require us to complete a sale of the assets of the Pharmaceutical Division on terms and conditions reasonably satisfactory to the lenders under the DIP Financing by a certain date, with the further requirement that milestones in the sale process be completed by specified dates. If we are unable to complete a sale of the Pharmaceutical Division on acceptable terms on a timely basis, we may be in default of any DIP Financing that we are able to obtain and, as a result, we may not have access to a source of liquidity necessary to continue to operate our business and may be required to cease operations and liquidate our assets.

Our substantial indebtedness severely limits cash flow available for our operations and impairs our ability to service debt or obtain additional financing if necessary.

We are highly leveraged. We currently have $165.0 million in senior term loans outstanding. We cannot borrow additional amounts under the senior term loans. We also have a senior revolving credit facility in the amount of $15.0 million, of which loans aggregating $10.8 million are outstanding as of April 25, 2005. We may not borrow additional funds under this revolving credit facility without the consent of our senior lenders. In addition, we have $175.0 million of our senior subordinated notes outstanding. We have granted the lenders under our senior credit facilities a lien on substantially all of our current and future property, including our intellectual property, and we have granted a second-priority lien on these assets to secure our senior subordinated notes and the guarantees of the notes by certain of our subsidiaries. The terms of our senior secured credit facilities and the indenture governing our senior subordinated notes severely restrict our ability to obtain funds by incurring further indebtedness.

Among other things, the substantial amount of payments on our outstanding debt and other payment obligations:

80

	•	limits our ability to obtain additional financing,
	•	limits our flexibility in planning for, or reacting to, changes in our business and the industry,
	•	places us at a competitive disadvantage relative to our competitors with less debt,
	•	renders us more vulnerable to general adverse economic and industry conditions, and
	•	requires us to dedicate a substantial portion of our cash flow to service our debt.

Our ability to make future payments on, and, if necessary, to refinance our debt, will depend on our ability to restructure our debt and generate cash in the future, which may be influenced by general economic, business, financial, competitive, legislative, regulatory and other factors beyond our control. We cannot assure you that we will be able to restructure our debt or that our business will generate sufficient cash flow from operations or that future borrowings will be available in an amount sufficient to enable us to make scheduled interest payments on our debt or repay our debt on or before maturity. As noted above, our failure to pay the $10.5 million of scheduled interest due on April 1, 2005 on our notes could result in an acceleration of our notes.

Our near-term liquidity and cash flow may be significantly affected by pharmaceutical product chargebacks and returns.

Each of our pharmaceutical products may be returned to us near the expiration date of the product. We also have established contract prices for certain indirect customers that are supplied by our wholesale customers. A chargeback represents the difference between the cash payments we have received from our wholesale customers, which is the current published wholesale acquisition cost, and the indirect customers’ contract prices. At December 31, 2004, we had $24.6 million in allowances for customer credits, which primarily consist of reserves we established to cover estimated future chargebacks and estimated future product returns. These reserves are necessary because we must either issue a credit on future sales or make a cash payment when a chargeback is issued or when wholesalers exercise their rights of return for our pharmaceutical products as the products near expiration. In addition, a specialty wholesaler had $11.1 million of our Brethine injectable product in inventory as of December 31, 2004. We are accounting for the shipment of this product under the consignment method. We expect that this specialty wholesaler will return a significant portion of this product to us, and this wholesaler is currently setting off payments owed to us for other purchases of our pharmaceutical products against this return exposure. If our customers exercise their rights of return for products we have previously sold or request us to issue a chargeback for products that are sold to our indirect customers, the issuance of either a credit on future sales or cash payment resulting from such returns and chargebacks could have a material effect on our liquidity in 2005. In March 2005, we received a return request for approximately $2.8 million of our Darvon and Darvocet products.

81

Pharmaceutical product customers’ concerns with respect to our liquidity and potential bankruptcy filing may continue to have an adverse effect on our near-term liquidity and cash flow.

Concern by wholesalers with respect to our liquidity, potential bankruptcy filing and ability to make payments with respect to product returns or chargebacks may continue to have an adverse effect on our near-term liquidity and cash flow. Our wholesalers are under no contractual obligation to purchase our pharmaceutical products. We have seen a recent downturn in purchases of our pharmaceutical products that we believe to be the result of wholesalers limiting their exposure to us due to our liquidity position and potential bankruptcy filing. In addition, a significant wholesale customer has indicated to us that it will not pay for current purchases of pharmaceutical products until its exposure for potential product return and chargeback payments is reduced below a specified level. Accordingly, current sales to this significant wholesaler have not resulted in corresponding cash payments to us. Finally, to the extent that wholesaler channel inventories of our products exceed appropriate levels, our sales of those products in subsequent periods, and thus our cash flow, may be adversely affected.

Customers’ concerns with respect to our liquidity and potential bankruptcy filing and pending governmental investigations and litigation could make it difficult for us to obtain and retain fee-for-service projects.

Some customers and potential customers of our AAI Development Services Division have expressed concern with respect to issues regarding our liquidity and potential bankruptcy filing and pending governmental investigations and litigation in deciding whether to place, or continue, product development projects with us. Customer concerns regarding our uncertain financial condition have adversely affected our ability to obtain new engagements in our AAI Development Services Division, particularly long-term product development engagements. In the event of any filing under chapter 11 of the Bankruptcy Code, customer concerns about our ability to continue to perform product development projects may be significantly heightened. If we are unsuccessful in overcoming these customer concerns, we may fail to obtain new product development projects or retain existing product development projects, which would have a material adverse effect on our results of operations, financial condition and cash flow.

We are incurring significant professional fees, including in connection with governmental investigations and pending litigation, that are depleting our cash resources.

We have incurred, and in the near term likely will continue to incur, significant professional fees in connection with the pending governmental investigations and litigation described in Part I, Item 3, “Legal Proceedings” of this Annual Report on Form 10-K and in connection with a bankruptcy proceeding assuming we seek relief under chapter 11 of the bankruptcy Code. We are paying significant professional fees to FTI Palladium Partners for help in addressing our financial and liquidity concerns and other administrative services. We have also agreed to pay the fees and expenses of the legal counsel to the ad hoc committee of holders of our senior subordinated notes and the committee’s financial advisor and in connection with our discussions with that committee. We will also incur fees payable to our financial advisor in connection with potential asset sales. Further, we have incurred, and may continue to incur, significant professional fees in connection with our debt restructuring process and in connection with

82

evaluating and improving our internal controls over financial reporting, including in connection with our efforts to document our internal controls as required by Section 404 of the Sarbanes-Oxley Act of 2002. Professional fees on a number of the matters described in this report, including securities, stockholder derivative and ERISA litigation and governmental investigations, may extend for several years. These professional fees have substantially increased, and in the near term may continue to substantially increase, our cash needs to an extent that cash from our operations may be insufficient to fund all of our cash needs.

Risks Relating to Pending Governmental Investigations and Lawsuits

An adverse judgment in litigation in which we and certain current and former executive officers, employees and directors are defendants could have a material adverse effect on our results of operations and liquidity.

We, certain of our current and former officers and directors, and our independent registered public accountants have been named as defendants in purported stockholder class action lawsuits alleging violations of federal securities laws. The securities lawsuits were filed beginning in February 2004 and are pending in the U.S. District Court for the Eastern District of North Carolina. By order dated April 16, 2004, the district court consolidated the securities lawsuits into one consolidated action, and on February 11, 2005 the plaintiffs filed a consolidated amended complaint. The amended securities complaint asserts claims arising under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder on behalf of a class of purchasers of our common stock during the period from April 24, 2002 through and including June 15, 2004. The securities complaints allege generally that the defendants knowingly or recklessly made false or misleading statements during the Class Period concerning our financial condition and that our financial statements did not present our true financial condition and were not prepared in accordance with generally accepted accounting principles. The amended securities complaint seeks certification as a class action, unspecified compensatory damages, attorneys’ fees and costs, and other relief.

A stockholder derivative suit was filed in the United States District Court for the Eastern District of North Carolina on August 26, 2004 by two putative shareholders against current and former members of our Board of Directors and senior management. Our company is named as a “nominal defendant.” The complaint alleges that the individual director and officer defendants breached fiduciary and contractual obligations to our company by implementing an inadequate system of internal controls, and causing our company to issue false and misleading statements exposing our company to securities fraud liability, and that certain defendants engaged in insider trading. The complaint seeks unspecified compensatory damages, attorneys’ fees and costs, and other relief.

In addition, we, certain of our current and former directors, officers and employees and others have been named in a purported class action brought by an aaiPharma pension plan participant and beneficiary asserting claims under ERISA on behalf of a class of all persons who are or were participants or beneficiaries of the aaiPharma Inc. Retirement and Savings Plan during the period from April 24, 2002 to June 15, 2004. An amended complaint was filed on March 14, 2005 which alleges generally that the defendants breached fiduciary duties owed under ERISA with respect to the prudence and lack of diversification of investment of Plan assets in our common

83

stock, by misleading participants and beneficiaries of the Plan regarding our earnings, prospects, and business condition, by failing to act in the sole interest of Plan participants, and by failing to monitor the actions of other Plan fiduciaries. The complaint seeks certification as a class action, unspecified compensatory damages, attorneys’ fees and costs, and other equitable relief. This ERISA lawsuit is pending in U.S. District Court for the Eastern District of North Carolina. The proceedings in this matter will be coordinated with the securities lawsuits described above.

These lawsuits are at an early stage. Our response to the amended securities complaint is not due until May 26, 2005, and our response to the amended ERISA complaint is not due until June 30, 2005 at the earliest. By agreement, no response to the derivative suit is due until 60 days after the plaintiffs file their amended complaint, and no discovery has yet occurred in either the securities or derivative litigation. Only limited discovery has occurred in the ERISA litigation.

In addition to the foregoing matters, we are also a party to several other lawsuits. We are involved in two lawsuits centered on our omeprazole-related patents, including one lawsuit brought by us against an alleged infringer of our patents and another lawsuit which was brought by a third party against us and is currently essentially inactive. Omeprazole is the active ingredient found in Prilosec, a drug sold by AstraZeneca PLC. In August 2004, CIMA Labs, Inc. initiated a lawsuit against us in Minnesota state court seeking to recover the $11.5 million “break-up fee” paid to us pursuant to the merger agreement that we had entered into with CIMA on August 5, 2003, as well as $5 million in other costs. In addition, we are a party to a lawsuit pending in federal court in Georgia against Athlon Pharmaceuticals, Inc. regarding an agreement pursuant to which Athlon was to provide a contract sales force. Athlon is seeking to recover damages in connection with the termination of this agreement. Athlon has also filed a separate action against us in the same court alleging a breach of the purchase agreement pursuant to which we purchased Darvocet A500 from Athlon.

Although we intend to vigorously pursue all of our claims and defenses available in these lawsuits, an adverse determination in these lawsuits or an inability to obtain payment under our directors and officers liability insurance (“D&O insurance”) policies for litigation and indemnification costs in the securities matters and derivative action and any damages ultimately borne by us as a result of these lawsuits could have a material adverse effect on our business, financial condition, results of operations or cash flows. See Note 13 of Notes to Consolidated Financial Statements included in Part II, Item 8 “Financial Statements and Supplementary Data.”

An adverse outcome with respect to investigations of aaiPharma that are being conducted by the SEC and the U.S. Attorney’s Office could have a material adverse effect on our results of operations and liquidity.

In April 2004, in connection with an investigation conducted by the U.S. Attorney’s Office for the Western District of North Carolina (the “U.S. Attorney’s Office”), we received federal grand jury subpoenas for document production and potential testimony related to, among other things, certain transactions regarding our 2002 and 2003 financial information, the terms, conditions of employment and compensation arrangements of certain of our senior management personnel, compensation and incentive arrangements for employees responsible for the sale of our Brethine, Darvocet, calcitriol, azathioprine and Darvon Compound products, quantities of the foregoing products in distribution channels, financial benefits with respect to specified corporate

84

transactions to our senior management and others, certain loans obtained by us, extensions of credit, if any, by us to officers or directors, accounting for sales and returns of our foregoing products, our analysts’ conference calls on financial results, internal and external investigations of pharmaceutical product sales activities, and related matters. The SEC has also commenced an investigation and we have received a subpoena from the SEC covering similar matters.

We have agreed to cooperate fully with the government investigations and share with the SEC and the U.S. Attorney’s Office all results of the Special Committee’s investigation of unusual sales of certain of our products and other matters. The U.S. Attorney’s Office, SEC and other government agencies that are investigating or might commence an investigation of aaiPharma could impose, based on a claim of fraud, material misstatements, violation of false claims law or otherwise, civil and/or criminal sanctions, including fines, penalties, and/or administrative remedies. If any government sanctions are imposed, which we cannot predict or reasonably estimate at this time, our business, and financial condition, results of operations or cash flows could be materially adversely affected. These matters have resulted, and are expected to continue to result, in a significant diversion of management’s attention and resources and in significant professional fees.

In addition, there may be additional governmental investigations pending of which we are not yet aware.

We have certain obligations to indemnify our officers and directors and to advance expenses to such officers and directors , and we may not have sufficient insurance coverage available for this purpose. We may be forced to pay these indemnification costs directly, and we may not be able to maintain existing levels of coverage, which could make it difficult to attract or retain qualified directors and officers.

Our bylaws require that we indemnify our directors and officers under specified circumstances. We have also agreed to advance expenses to certain of our directors and current and former officers in connection with investigations by the SEC and the U.S. Attorney’s office. Although we have purchased D&O liability insurance for our directors and officers to fund a portion of these obligations, if our insurance carriers should deny coverage, or if the indemnification costs exceed the insurance coverage, we may be forced to bear some or all of these indemnification costs directly, which could be substantial and may have an adverse effect on our business, financial condition, results of operations and cash flows. Our insurance carrier has initially denied coverage with respect to claims made in connection with the pending ERISA litigation, though we have made a new demand for coverage under this policy based on the claims contained in the amended complaint. If the cost of this insurance increases significantly, or if this insurance becomes unavailable, we may not be able to maintain or increase our levels of insurance coverage for our directors and officers, which could make it difficult to attract or retain qualified directors and officers.

85

Concerns with respect to our liquidity, and the circumstances surrounding our pending litigation and governmental investigations and recent management changes and reductions in force could make it difficult for us to retain and hire critical personnel.

Concerns with respect to our liquidity and the investigations by the SEC and/or the U.S. Attorney’s Office and pending securities and ERISA class actions and other litigation, and recent changes to our management team and reductions in force, have created substantial uncertainty regarding our ability to focus on our business operations and remain competitive with other companies in our industry. Because of this uncertainty, we may have difficulty retaining critical personnel or replacing personnel who leave aaiPharma. In addition, due to the recent substantial declines in the price of our common stock, the exercise price of outstanding employee stock options substantially exceeds the trading price of our common stock. We also have made matching contributions to our 401(k) plan that were invested in our common stock. The loss in value of these stock options and 401(k) investments may affect our ability to retain our critical employees, which could seriously harm our ability to generate revenue, manage day-to-day operations, and deliver our products and services. A substantial number of employees have voluntarily left aaiPharma in 2004 and we may continue to lose critical personnel.

Risks Related to Our Business

Our internal control over financial reporting has been inadequate and may continue to be inadequate and could adversely affect our financial condition and ability to carry out our business plan.

In connection with the preparation of our 2003 Form 10-K, our then Chief Executive Officer and then interim Chief Financial Officer concluded that, as of December 31, 2003, our disclosure controls and procedures were not adequate. In addition, management has recently completed the process of assessing the effectiveness of our internal control over financial reporting, as required by Section 404 of the Sarbanes-Oxley Act. Based on their assessment, our Chief Executive Officer and Chief Financial Officer have concluded that our internal control over financial reporting was not effective as of December 31, 2004 due to the existence of numerous material weaknesses. A detailed description of these material weaknesses is included in Part I, Item 8 “– Management Report on Internal Control Over Financial Reporting.”

In order to remediate the numerous material weaknesses in our internal control over financial reporting, we have devoted, and will be required to continue to devote, significant financial resources and management attention to our remediation efforts. Due to our liquidity constraints, we may not be able to devote sufficient financial resources to successfully remediate the material weaknesses in our internal controls that we have identified. In addition, our management is currently focused on dealing with our liquidity issues while continuing to operate our business, and thus may not be able to devote sufficient time and attention to our remediation efforts.

If we are not successful in addressing these material weaknesses, we may be unable to produce accurate and reliable financial reports on a timely basis or at all. In addition, if we do not have effective internal control over financial reporting, we may be exposed to an increased likelihood of financial fraud. If we cannot provide accurate and reliable financial reports and do not have internal controls that provide reasonable assurance that financial fraud will be prevented,

86

investors, lenders, customers or suppliers could lose confidence in our reported financial information and our liquidity, access to capital markets, business and operating results could be harmed.

We may have overpaid for our branded product lines, which may not produce sufficient cash flow to repay indebtedness incurred in connection with the acquisition or to provide an acceptable rate of return on our investment.

Beginning in 2001, we increased our net revenues through a series of acquisitions of branded products. The acquisition prices that we paid were based upon many factors, including our analysis of sales history, forecasted sales, competition, and our judgment with respect to marketing potential, brand strength and product improvement opportunities. The revenues we derive from any of these product lines may be lower than amounts we expected when we acquired these product lines. We funded our significant product acquisitions, including Brethine, Darvon, Darvocet, Oramorph SR, Roxanol, and Roxicodone, with borrowings under predecessor senior credit facilities, and the net proceeds from our sale of the Notes. We may have overpaid for our branded product lines, and they may not produce sufficient cash flow to repay indebtedness incurred in connection with the acquisition or to provide an acceptable rate of return on our investment.

Our branded products are subject to generic competition and increased generic substitution for our branded products may result in a decrease in our revenues and materially affect our liquidity.

Our branded products are subject to generic competition. In early 2004, the Food and Drug Administration approved generic versions of our Roxicodone and Brethine injectable products. There is no proprietary protection for most of the branded pharmaceutical products that we sell, and as a result our branded pharmaceutical products are or may become subject to competition from generic substitutes. In May 2004, a generic version of injectable Brethine was introduced, which has significantly adversely affected our sales of that product (both as a result of a reduction in volume and pricing) and is expected to continue to do so and may result in the return of product sold in prior periods as the product’s shelf life nears expiration. In the second half of 2004, we recorded charges of $6.4 million due to the impairment of an intangible asset associated with our Brethine product because the introduction of generic competition adversely affected our future anticipated revenues, which negatively impacted the carrying value of such intangible asset. In addition, given levels of inventory of this product in the distribution channel, our cash flows from sales of this product may be negatively affected and we may experience significant returns of this product which could materially adversely affect our liquidity. Generic substitutes for our branded products, which may be identical to our branded products, are sold by competitors at significantly lower prices. If consumers and physicians do not believe that our branded products have greater benefits than their generic equivalents, they may elect generic equivalents or other substitute products in lieu of our branded products, which may result in decreased revenues for our branded products. Any further increase in the amount of generic and other competition against any one or more of our products could further lower prices and unit sales. In addition, pressures to reduce pharmaceutical costs, including from third-party payers such as health maintenance organizations, or HMOs, and health insurers, may result in physicians or pharmacies increasingly using generic substitutes. State and federal legislation,

87

and decisions by state and federal government agencies with the power to determine or influence purchasing decisions on products sold to government agencies or through government-funded programs, may be enacted or made that would adversely affect purchases of branded pharmaceutical products. Such legislation or government agency decisions may more broadly mandate substitution of generic products for prescriptions written for branded products, establish preferred or exclusionary product lists that favor generic products, or otherwise establish or influence product purchases. Competition from generic products or additional legislation or regulatory developments favoring generic products, creating preferred or exclusionary product lists, or establishing or influencing purchasing decisions, could cause our sales of branded products to decrease and could have a material adverse effect on our business, financial condition, and results of operations.

A small number of customers account for a large portion of our sales and the loss of one of them, or changes in their purchasing or payment patterns or inventories, could result in reduced sales or adversely impact our financial performance.

We are heavily dependent on sales of our products to three large national wholesalers, McKesson Corporation, Cardinal Health Inc., and AmerisourceBergen Corporation, which then resell our products out of their inventories to pharmacies and other indirect customers for use in meeting ultimate prescription demand. Our results of operations, including, in particular, product sales revenue, may vary from quarter to quarter due to buying and payment patterns and inventories of our wholesalers. A significant wholesale customer has indicated to us that it will not pay for current purchases until its exposure for potential product return and chargeback payments is reduced below a specified level. Accordingly, current sales to this significant wholesaler have not resulted in corresponding cash payments to us. In the event wholesalers with whom we do business determine to limit their purchases of our inventory or withhold payments from us, sales of our products or our cash flows could be materially adversely affected. In addition, we believe that excess sales of our Brethine injectable and Darvocet N-100 products during the second half of 2003 significantly reduced our sales of these products in 2004. The small number of wholesale drug distributors, consolidation in this industry, changes in the business model of such wholesale drug distributors or financial difficulties of these distributors could result in the combination or elimination of warehouses, which could temporarily increase returns of our products or, as a result of distributors reducing inventory levels, delay the purchase of our products.

We do not anticipate receiving further material payments in connection with our significant development agreement in the future, and we may be unable to replace this revenue stream.

We have a significant development agreement under which we received product development revenues of $17.7 million in 2004, $13.0 million in 2003 and $16.9 million in 2002 and development services revenues of $0.7 million in 2004, $2.7 million in 2003 and $4.7 million in 2002. During this time period, we recorded research and development expenses of zero in 2004, $1.0 million in 2003 and $0.7 million in 2002 related to this agreement. In April 2004, we entered into an agreement to receive a prepayment of amounts that would otherwise be paid to us quarterly through the second quarter of 2005 under this significant development agreement. These payments would have aggregated $15.4 million, and in April 2004 we received approximately $15.0 million in gross proceeds from the prepayment. We do not anticipate that

88

we will receive any further payments in connection with this significant development agreement in the future. If we are unable to replace this revenue stream, our results of operations and cash flows may be materially adversely affected.

We are dependent on third parties for the manufacture of our products and for critical raw materials and services.

We are dependent on third parties for certain essential business functions, and problems with these third-party arrangements could materially adversely affect our ability to manufacture and sell products and our business, financial condition, and results of operations.

We are dependent on third parties for the manufacture of certain of our pharmaceutical products. Our manufacturing dependence upon third parties may adversely affect our profit margins and our ability to deliver our products on a timely and competitive basis. We have entered into supply agreements with our third-party manufacturers that obligate them to supply us with products. However, if we are unable to timely pay for such products, our third party manufacturers may be able to terminate their obligations to supply our needs. If we are unable to retain or replace third-party manufacturers on commercially acceptable terms and on a timely basis, we may not be able to distribute our products as planned. If we encounter delays or difficulties with contract manufacturers in producing or packaging our products, the distribution, marketing and subsequent sales of these products will be adversely affected, and we may have to seek alternative sources of supply, lose sales or abandon or divest a product line on unsatisfactory terms. We may be unable to enter into alternative supply arrangements at commercially acceptable rates on a timely basis, if at all. The manufacturers that we use may not be able to provide us with sufficient quantities of our products, and the products supplied to us may not meet our specifications. Moreover, failure of our contract manufacturers to follow good manufacturing practices as mandated by the FDA, could suspend or halt manufacturing at these sites. Additionally, modifications, enhancements, or changes in manufacturing sites of approved products are subject to FDA approval that we may not be able to obtain and that may be subject to a lengthy application process.

After expiration of our existing third-party supply contracts, our manufacturing costs for those products supplied under these contracts could be higher and any transfer of manufacturing of these products, including any transfer to our own or new third-party manufacturing facilities, may cause us to incur significant manufacturing start-up costs. Our third-party supply contracts are scheduled to expire beginning over the next few years, and we may be unable to renew agreements with our current suppliers because in a number of cases our suppliers are companies from whom we acquired our branded products and the supply agreements were entered into in connection with the purchase of the branded product line. Additionally, any change of the manufacturing site of any of these products would require FDA approval of the new manufacturing facility. FDA approval, however, is not within our control, and we may not receive t